US20220331514A1 - Multiport delivery device - Google Patents
Multiport delivery device Download PDFInfo
- Publication number
- US20220331514A1 US20220331514A1 US17/697,755 US202217697755A US2022331514A1 US 20220331514 A1 US20220331514 A1 US 20220331514A1 US 202217697755 A US202217697755 A US 202217697755A US 2022331514 A1 US2022331514 A1 US 2022331514A1
- Authority
- US
- United States
- Prior art keywords
- syringe
- inlet
- medication
- medications
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012384 transportation and delivery Methods 0.000 title description 33
- 239000003814 drug Substances 0.000 claims abstract description 153
- 229940079593 drug Drugs 0.000 claims abstract description 151
- 238000001990 intravenous administration Methods 0.000 claims abstract description 87
- 238000002483 medication Methods 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims description 46
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000000151 anti-reflux effect Effects 0.000 claims description 17
- 238000001802 infusion Methods 0.000 claims description 16
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 10
- 229960004134 propofol Drugs 0.000 claims description 10
- 230000003444 anaesthetic effect Effects 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 206010002091 Anaesthesia Diseases 0.000 description 32
- 230000037005 anaesthesia Effects 0.000 description 32
- 230000006698 induction Effects 0.000 description 18
- 206010011409 Cross infection Diseases 0.000 description 14
- 239000003570 air Substances 0.000 description 13
- 239000000645 desinfectant Substances 0.000 description 13
- 206010040047 Sepsis Diseases 0.000 description 12
- 238000002627 tracheal intubation Methods 0.000 description 12
- 208000037815 bloodstream infection Diseases 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000005201 scrubbing Methods 0.000 description 11
- 238000009987 spinning Methods 0.000 description 10
- 238000011109 contamination Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- -1 chemotherapeutics Substances 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 229960004194 lidocaine Drugs 0.000 description 7
- 239000000842 neuromuscular blocking agent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- 229960002428 fentanyl Drugs 0.000 description 6
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000002695 general anesthesia Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 description 4
- 229960000491 rocuronium Drugs 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 4
- 229940032712 succinylcholine Drugs 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 3
- 230000003109 amnesic effect Effects 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 229960001139 cefazolin Drugs 0.000 description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 3
- 229960001690 etomidate Drugs 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000002576 laryngoscopy Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 3
- 229960003793 midazolam Drugs 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000012503 Bathing suit ichthyosis Diseases 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010022773 Intracranial pressure increased Diseases 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000001062 anti-nausea Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- LVRSYEPLVIJQRJ-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene;2-methylbuta-1,3-diene Chemical compound CC(=C)CBr.CC(=C)C=C LVRSYEPLVIJQRJ-UHFFFAOYSA-N 0.000 description 1
- HUGXNORHVOECNM-UHFFFAOYSA-N 3-chloro-2-methylprop-1-ene;2-methylbuta-1,3-diene Chemical compound CC(=C)CCl.CC(=C)C=C HUGXNORHVOECNM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000034896 Device use error Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000030489 Increased intracranial pressure disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940127248 antinauseant drug Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- HIHIPCDUFKZOSL-UHFFFAOYSA-N ethenyl(methyl)silicon Chemical compound C[Si]C=C HIHIPCDUFKZOSL-UHFFFAOYSA-N 0.000 description 1
- 229920006213 ethylene-alphaolefin copolymer Polymers 0.000 description 1
- 229920005680 ethylene-methyl methacrylate copolymer Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920006216 polyvinyl aromatic Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920006215 polyvinyl ketone Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920006214 polyvinylidene halide Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 229940068944 providone-iodine Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 208000036273 reactive airway disease Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
- 229960003819 vecuronium Drugs 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940072018 zofran Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
- A61M5/1408—Infusion of two or more substances in parallel, e.g. manifolds, sequencing valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M39/105—Multi-channel connectors or couplings, e.g. for connecting multi-lumen tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M39/1055—Rotating or swivel joints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M39/24—Check- or non-return valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/36—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests with means for eliminating or preventing injection or infusion of air into body
- A61M5/38—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests with means for eliminating or preventing injection or infusion of air into body using hydrophilic or hydrophobic filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M2005/1401—Functional features
- A61M2005/1406—Minimizing backflow along the delivery catheter track
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0241—Anaesthetics; Analgesics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Definitions
- the present invention relates generally to multi-port, multi-formulation introduction devices.
- IV delivery devices that can allow a physician, advanced practice nurse, nurse, provider, or the like to deliver several time sensitive formulations such as medications while reducing and/or eliminating chances of infection, particle infusion, air infusion, or a combination thereof.
- devices for delivering at least two different medications are described.
- the devices can deliver two, three, four, five, six, seven, eight, nine, ten, or more medications.
- the devices can comprise a body section including at least two inlet ports.
- at least one of the at least two inlet ports includes an anti-reflux valve and is operably connected to a first filter.
- one of at least two inlet ports includes an anti-reflux valve and is operably connected to a first filter and another inlet port of the at least two inlet ports includes an anti-reflux valve and is operably connected to a second filter.
- the devices can further include a rotating outlet port joined to the first filter and the second filter by a y-connector and configured to connect to an intravenous line.
- the outlet port can be a fixed luer lock.
- the devices can be torqued, spun, and/or rotated while delivering the at least two different medications without loosening the outlet port from the intravenous line.
- the first filter can be a 0.2 ⁇ m filter and the second filter can be a 5 ⁇ m filter. In some embodiments, at least one inlet port flows into the first filter and at least one inlet port flows into the second filter.
- the at least two inlet ports described can be scrubbable inlet ports.
- the devices can include two inlet ports.
- the devices can include four or eight or more inlet ports.
- the devices described can have a minimal amount of dead space within the devices and/or the device lines.
- the rotating outlet port includes a gear and a pawl that can allow rotation without loosening the outlet port from the intravenous line.
- the outlet port on the devices can be a male luer lock.
- the male luer lock can be a spinning male luer lock.
- the male luer lock can also be a fixed luer lock that does not spin.
- Methods are also descried for using the herein described devices. Methods can include methods of delivering at least two different time sensitive medications. These methods can include delivering at least a first medication in a first syringe and a second medication in a second syringe through a device into an intravenous line without disconnecting the first syringe or the second syringe.
- the medications delivered using the described methods can be anesthetics.
- an anesthetic can be propofol.
- the methods can utilize a device that comprises a body section including at least two inlet ports.
- at least one of the at least two inlet ports includes an anti-reflux valve and operably connected to a first filter and another inlet port of the least two at least one additional of the at least eight inlet ports includes an anti-reflux valve and operably connected to a second filter.
- the methods can further comprise delivering at least a third medication in a third syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, or the third syringe.
- the methods can include delivering at least a fourth medication in a fourth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, or the fourth syringe.
- the methods can include delivering at least a fifth medication in a fifth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, or the fifth syringe.
- the methods comprise delivering at least a third medication in a third syringe, a fourth medication in a fourth syringe, a fifth medication in a fifth syringe, a sixth medication in a sixth syringe, a seventh medication in a seventh syringe, and an eighth medication in an eighth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, the fifth syringe, the sixth syringe, the seventh syringe, or the eighth syringe.
- FIG. 1 illustrates an example embodiment of a device as described herein.
- FIG. 2A is a front perspective view of a hub as described herein.
- FIG. 2B is a back perspective view of a hub as described herein.
- FIG. 3A is a back view of a hub as described herein.
- FIG. 3B is a side view of an exemplary hub.
- FIG. 3C is a front view of the hub in FIG. 3B .
- FIG. 3D is a side view of another exemplary hub.
- FIG. 3E is a front view of the hub in FIG. 3D .
- FIG. 4A illustrates an assembly of a spinning connection as described herein.
- FIG. 4B illustrates the male connection of FIG. 4A .
- FIG. 4C illustrates the female connection of FIG. 4A .
- FIG. 4D illustrates a component of the assembly in FIG. 4A .
- FIG. 4E is a cross-section as indicated in FIG. 4A .
- FIG. 4F is another cross-section as indicated in FIG. 4A .
- FIG. 5 illustrates an embodiment where a hub is distant to the body of the device.
- FIG. 6 is an illustration of a device assembled with eight syringes.
- IV infusion devices that can reduce and/or eliminate chances of infection, particle infusion, air infusion, or a combination thereof when used as directed.
- the devices can alleviate the need for IV port aseptic preparing and/or scrubbing between time sensitive medication deliveries.
- the multi-lumen devices can be anesthesia induction devices.
- Anesthesia delivery can be extremely time sensitive, and delivering anesthesia with the described devices can reduce the time burden on medication delivery.
- These devices can be scrubbable, for example, at any and all introduction ports or exit ports in the devices.
- the devices can be self-priming meaning that air and particulates can be removed from solution(s) being delivered through the device.
- HAIs healthcare-associated infections
- Central venous catheters play an integral role in modern health care, allowing for the administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as providing hemodialysis access and hemodynamic monitoring.
- CVCs central venous catheters
- Central venous catheters are the most frequent cause of healthcare-associated bloodstream infections, called central line-associated bloodstream infections (CLABSI).
- CLABSIs An estimated 330,000 CLABSIs occur each year in the United States, 80,000 of those occur in the intensive care unit (ICU). CLABSIs are serious but often preventable infections when evidence-based guidelines are followed for the insertion and maintenance of central lines.
- CLABSIs also increase the cost of health care and prolonged hospital stays by up to three weeks.
- Non-inflation-adjusted costs associated with CLABSIs have varied from $3,700 per infection to $36,441 per infection.
- a recent CDC estimate set the cost of each CLABSI at $16,550.
- IV infusion devices that can reduce and/or eliminate chances of infection.
- Devices that can reduce and/or eliminate infection are disclosed herein.
- Rapid sequence induction also described as rapid sequence intubation (RSI) is an advanced airway management medical procedure used to achieve tracheal intubation under the induction of anesthesia in patients who are at high risk of pulmonary aspiration. Rapid sequence intubation refers to the pharmacologically induced sedation and neuromuscular paralysis prior to intubation of the trachea. The technique is a quicker form of the process normally used to induce general anesthesia.
- Rapid sequence induction involves pre-filling the patient's lungs with a high concentration of oxygen gas, followed by administering rapid-onset hypnotic and neuromuscular-blocking drugs that induce prompt unconsciousness and paralysis, allowing tracheal intubation with minimal delay. Unlike other methods of induction, no artificial ventilation is provided from the time that drugs are administered until after intubation has been achieved; this minimizes insufflation of air into the stomach, which might otherwise lead to regurgitation. But also requires rapid airway management and intervention as the patient is apneic and will begin to develop oxygen-hemoglobin desaturation.
- Rapid sequence induction is used where general anesthesia must be induced before the patient has had time to fast long enough to empty the stomach; where the patient has a medical condition that makes aspiration more likely during induction of anesthesia, regardless of how long they have fasted (such as gastro-esophageal reflux disease); or where the patient has become unable to control their own airway even before anesthesia (such as with the critically ill or after a traumatic brain injury).
- RSI RSI is initiated in an Emergency Room, Operating Room and/or the Intensive Care Unit. It is also utilized outside of these typical hospital settings and can occur in the Emergency Medical Response settings within the scope of the practice of paramedics, firefighters, and other healthcare professionals.
- the induction drugs preferentially used in RSI have short durations of action, wearing off after only minutes. This confers a degree of fault tolerance on the procedure when it is used in elective or semi-elective settings: if intubation is unsuccessful, and if the clinical condition allows it, the procedure may be abandoned and the patient should regain the ability to protect their own airway sooner than would be the case under routine methods of induction. Conversely, in emergency settings where the patient's condition does not allow for them to be woken up immediately, a failed RSI places them at very high risk for respiratory compromise.
- Commonly used medications during a rapid sequence intubation include, but are not limited to, sedatives such as midazolam, ketamine, fentanyl, propofol, and etomidate, paralytics such as succinylcholine, rocuronium, vecuronium, and other medications such as atropine for patients where bradycardia is a concern, and ephedrine where hypotension may occur secondary to the sedating drugs.
- sedatives such as midazolam, ketamine, fentanyl, propofol, and etomidate
- paralytics such as succinylcholine, rocuronium, vecuronium
- other medications such as atropine for patients where bradycardia is a concern
- ephedrine where hypotension may occur secondary to the sedating drugs.
- Pretreatment for RSI consists of the medications given to specific groups of high-risk patients minutes before the paralysis stage with the aim of protecting the patient from the adverse effects of introducing the laryngoscope and endotracheal tube. Intubation causes increased sympathetic activity, an increase in intracranial pressure and bronchospasm. Patients with reactive airway disease, increased intracranial pressure, or cardiovascular disease may benefit from pretreatment.
- Two common medications used in the pretreatment of RSI include, but are not limited to, lidocaine and atropine.
- Lidocaine has the ability to suppress the cough reflex which in turn may mitigate increased intracranial pressure. For this reason lidocaine is commonly used as a pretreatment for trauma patients who are suspected of already having an increase in intracranial pressure. The typical IV dose is given three minutes prior to intubation. Lidocaine is also theorized to blunt a rise in intracranial pressure during laryngoscopy, although this remains controversial and its use varies greatly.
- Atropine as a parasympathetic blocker, may also be used as a premedication agent in pediatrics to prevent bradycardia caused by hypoxia, laryngoscopy, and succinylcholine. Atropine may be used to prevent a reflex bradycardia from vagal stimulation during laryngoscopy, especially in young children and infants. Despite their common use, such adjunctive medications have not been demonstrated to improve outcomes.
- the patient With standard intravenous induction of general anesthesia, the patient typically receives an opioid, and then a hypnotic medication. Generally the patient will be manually ventilated for a short period of time before a neuromuscular blocking agent is administered and the patient is intubated.
- the person still receives an IV opioid.
- the difference lies in the fact that the induction drug and neuromuscular blocking agent are administered in rapid succession with no time allowed for manual ventilation.
- Commonly used hypnotics include thiopental, propofol and etomidate.
- Commonly used neuromuscular blocking agents used include succinylcholine and rocuronium. The neuromuscular blocking agents paralyze all of the skeletal muscles, most notably and importantly in the oropharynx, larynx, and diaphragm.
- Opioids such as Fentanyl may be given to attenuate the responses to the intubation process (accelerated heart rate and increased intracranial pressure). This is supposed to have advantages in patients with ischemic heart disease and those with brain injury (e.g. after traumatic brain injury or stroke).
- HFE Human Factor Engineering
- Human factor engineering is being implemented by the devices described herein through product enhancement to the following attributes: design, such as but not limited to, an ergonomic mold for handheld use and versatile compatibility, specific IV tubing ID/OD improving clinical effectiveness, specific IV tubing length adjusted for syringe accessibility, and luer collar distance from device body addressing ease of handling, materials such as but not limited to, clear PVC for fluid flow visualization, medical grade PVC for sterile applications, specified filter housing dimensions improving clinical effectiveness, specified filter membrane addressing removal of specific foreign bodies, and add on products such as, but not limited to, color coded IV tubing for fluid identification, color coded IV connectors for fluid identification, and molding, assembly and packaging by a single manufacturer.
- design such as but not limited to, an ergonomic mold for handheld use and versatile compatibility, specific IV tubing ID/OD improving clinical effectiveness, specific IV tubing length adjusted for syringe accessibility, and luer collar distance from device body addressing ease of handling, materials such as but not limited to, clear PVC for fluid flow visualization, medical grade PVC for sterile
- the devices in addition to the devices being self-priming, they can also produce low waste volume. In other words, the devices can function with minimal dead volume thus providing more accurate delivery of solution(s) through the devices.
- the devices described herein can also filter solution(s) that are introduced through the devices.
- the devices have one filter. In other embodiments, the devices have more than one filter.
- the presently described devices can prevent health care workers' inadvertent IV infusion of air, microorganisms, endotoxins, particulate matter, and/or lipid emboli into a patient.
- the devices described herein can be used to deliver solution(s), such as formulations or medications to a patient.
- the patient can be a mammal such as a human, cat, dog, horse, cow, bull, goat, bison, or the like.
- the devices can meet the highest safety standards imposed by local, regional, or governmental regulations for introduction and maintenance of formulation delivery.
- the devices can include at least two inlet ports, the devices can eliminate a need for multiple connections during introduction of formulations into a patient. Therefore, the devices can reduce overall time and the potential for contamination of the formulations during delivery. In other words, the devices can provide safe, efficient and reliable methods to perform multi-formulation delivery. In one embodiment, the devices described can assist in preventing healthcare-associated infections (HAI) which have become a growing problem in therapeutic and hospital settings.
- HAI healthcare-associated infections
- each port/hub/cap connector can possess an ability to be aseptically prepared and/or scrubbed and/or sterilized prior to connection for access of IV medications, can filter air, can filter particulate matter, can filter lipids, can filter microorganisms and endotoxins, can limit connection to only one access of the patient's IV tubing, can include one-way/anti-reflux valves to prevent retrograde IV fluid or blood flow, can include the ability to securely isolate chosen medications dedicated to one patient, can be easy to use during a single provider rapid sequence induction of medication, and/or can include minimal dead space within the fluid pathways.
- the devices described herein can include various combinations of cap/cap connectors, female lure locks, anti-reflux valves, micro-tubing, multi-lumen manifold, low volume filters, Y-connector, macro-tubing, and easy to use male lure lock(s).
- the systems can be customizable prior to manufacturing and individually distributed to healthcare providers as a one-time use device.
- the devices can improve patient safety and/or streamline the process of administering IV medications, such as anesthesia, through the reduction in errors of contaminations and infections of the patient's blood stream by eliminating inadvertent infusions of particulates and securely isolating IV medications for the use by one patient.
- the devices can employ the highest level of infection prevention standards set by the CDC (Centers for Disease Control and Prevention), TJC (The Joint Commission), SHEA (The Society for Healthcare Epidemiology of America), World Health Organization (WHO), National Institute of Health (NIH), United States Department of Health and Human Services (HHS), European Centre for Disease Prevention and Control, Centers for Medicare, and/or Medicaid Services.
- the devices can also reduce time associated with medication introduction by eliminating multiple connections and disconnections of medication syringes during the standard rapid introduction sequence.
- the CDC in 2011 provided the Guidelines for the Prevention of Intravascular Catheter-Related Infections. These guidelines have been developed for persons responsible for surveillance and control of infections in hospital and states at page 54: “[m]inimize contamination risk by scrubbing the access port with an appropriate antiseptic (chlorhexidine, povidone iodine, an iodophor, or 70% alcohol) and accessing the port only with sterile devices.”
- an appropriate antiseptic chlorhexidine, povidone iodine, an iodophor, or 70% alcohol
- the TJC recommends that a medical provider “scrub the hub you are accessing every time you use it” (CLABSI (central line associated blood stream infections) Toolkit: Valve Disinfection Guidance, Mar. 21, 2014). Scrubbing a hub every single time it is being accessed is a near impossible task when time sensitive medications, such as anesthesia, are being delivered.
- CLABSI central line associated blood stream infections
- SHEA has provided a 2014 Compendium which is a concise distillation of current guidelines for the prevention of HAIs that brings together recommendations from respected sources in a format suited to implementation in the clinical setting. It also includes metrics and indicators of success for implementation.
- the Compendium states that “[i]f CLABSI surveillance or other risk assessments suggest that there are ongoing opportunities for improvement, hospitals should then consider adopting some or all of the prevention approaches listed as special approaches”.
- the devices described herein can be categorized as a special approach under the 2014 Compendium.
- Port scrubbing is a CDC recommendation
- the TJC states mandatory port scrubbing prior to administration of IV medications
- SHEA considers “special approaches” for additional prevention of blood stream infections.
- the present devices can meet all these needs and more.
- Port Scrubbing is generally considered to require at least 15 seconds of scrubbing an access port with an appropriate antiseptic prior to the administration of every IV medication.
- Appropriate anesthetics can be, but are not limited to, chlohexadine, providone iodine, an iodophor, or 70% alcohol.
- the devices described herein can prevent and/or reduce the chance of a blood stream infection (BSI) and/or HAIs.
- Blood stream infections and/or HAIs can many times be associated with the contamination of IV ports and IV junctional connections during IV medication and IV fluid administration. Blood stream infections and/or HAIs are a great risk for patients that require IV medication therapy. Over 500,000 catheter-related BSIs occur in the United States every year, costing the United States healthcare system over $10 billion annually.
- a patient's blood stream is a dynamic and sterile environment that, once contaminated, can pose multiple life threatening problems. Contaminations of a patient's blood stream can occur via both endogenous (e.g., patient's skin flora) and extrinsic (e.g., health care workers' hands) exposure to the medication fluid pathways.
- endogenous e.g., patient's skin flora
- extrinsic e.g., health care workers' hands
- the most vulnerable populations are the immune compromised patients who include, but are not limited to, neonates, elderly, critically ill, hematology patients, oncology patients, transplant patients, and the like. Also vulnerable are those patients with an indwelling or implanted medical device including, but not limited to, central venous catheters (CVC), prosthetic joint, shunts, hardware, and the like.
- CVC central venous catheters
- Blood stream infections carry a high percentage of mortality for the vulnerable populations. It has been reported that BSIs have a reported mortality up to 25%. Blood Stream Infections can lead to endocarditis, osteomyelitis, sepsis, stroke, infected heart valves, infected joints, infected implanted devices and other life threatening illnesses.
- the presently described devices can reduce a patient's risk of infection by, in part, preventing connections and disconnections without proper or recommended port scrubbing.
- Every IV medication administration can also potentially allow embolic air and particles into the patient's blood stream. This occurs via the fluid pathway by way of IV injection ports.
- the present devices can eliminate or substantially reduce embolic air introduction into an IV line.
- Lipid based medication also poses a risk of inadvertent infusion of large globule molecules, which can lodge in the pulmonary vasculature compromising respiratory function.
- the present devices can eliminate or substantially reduce globule introduction into an IV line.
- the current techniques risk inadvertent infusion of particulate matter, air and lipid emboli, microorganisms and endotoxins that can be introduced to the patient's bloodstream via the inadvertent contamination of the IV medication, medication syringe, cap connector or access point connection.
- the probability of contamination dramatically increases with each IV access connection performed by a healthcare provider.
- the average induction and maintenance of anesthesia requires a range of 2-10 different IV medications, each requiring repeated connections and reconnections of separate syringes to and from the patient's IV tubing in a rapid sequence prior to initiation of airway management.
- the devices described herein can provide the highest-grade standards for all IV infusions.
- the devices described herein can also provide the safest and/or most efficient approach to the administration of IV anesthesia, especially during the induction sequence of multiple medications of which timed delivery is critical and 15 second scrub times for each port may not be possible without compromising the patient's safety.
- Medications can be loaded into separate syringes for delivery to a patient using the present devices without constant connections and disconnections.
- Medications that can be delivered using the presently described devices include, but are not limited to, anesthesia, antibiotics, saline, muscle relaxing agents, neuromusclar blocking agents, anxiolytics/amnesics, narcotics, stimulants, anti-nausea medications, chemotherapeutics, antimicrobials, steroids, non-steroidal anti-inflammatories, nerve blocks, vitamins, gene therapies, nutrients, emergency medications such as heart rate and blood pressure support medications, and the like.
- the medications can be anesthetics and the medications that support delivery of anesthesia.
- Anesthesia can include propofol and/or lidocaine.
- Antibiotics can include cefazolin which may require a saline flush. Saline can also be used to flush the device lines described herein. In one embodiment, a saline flush may be recommend to ensure the medications are delivered to the patient and are not retained within the device.
- Neuromuscular blocking agents can include rocuronium.
- Anxiolytics/amnesics can include midazolam. Narcotics can include fentanyl.
- Emergency medications can include phenylephrine, ephedrine, epinephrine and vasopressin.
- Anti-nausea medications can include ondansetron and dexamethasone.
- the enumerated medications are presented as non-limiting medications. Each anesthetic poses its unique challenges, and therefore the selection of medications represents the needs or potential needs of the patient and the type of surgery's anesthesia requirements. Some anesthesia cases require less than the categories/medications listed and some require more. In some embodiments, the combinations of medications required for anesthesia for a patient can be as few as two and as many as ten or more to complete an anesthetic.
- the delivery of the anesthesia can be extremely time sensitive.
- the devices described herein can assist and/or solve problems that exist with time sensitive delivery of the medications for anesthesia. For example if eight different medications are being delivered in an anesthetic treatment, including 15 second port scrub times between medications, two minutes would be spent simply cleaning the port between each medication delivery which does not account for the actual time for delivery. For example, if propofol is the first medication delivered, there is simply not sufficient time to scrub delivery ports and deliver subsequent medications without putting a patient at risk. Thus, often ports are not aseptically prepared and/or scrubbed and contaminations and patient infections can occur. Further, because infection is being introduced directly into the bloodstream, time to sufficiently disinfect inlet ports is absolutely critical. The present devices solve these and other problems.
- the device in combination with positive pressure, continuous flow infusion pump, is intended to deliver fixed doses of medication upon demand by the patient or healthcare provider.
- Device 100 can include an outlet 102 .
- Outlet 102 can be configured to be connected to an IV line or other introduction line.
- Outlet 102 can be of a standard line connector or can include anti-torqueing or spinning connectors as will be described in greater detail herein.
- outlet can be a standard, fixed luer connection.
- device 100 is for single patient use.
- Device 100 can include at least two or more inlet lines 104 that interface or otherwise meet at hub 106 . Each of the at least two or more inlet lines 104 can be the same or different size line.
- device 100 includes a first inlet line 108 , a second inlet line 110 , a third inlet line 112 , a fourth inlet line 114 , a fifth inlet line 116 , a sixth inlet line 118 , a seventh inlet line 120 , and an eighth inlet line 122 . More than eight inlet lines can be included in device 100 . For example, nine, ten, eleven, twelve, 13, 14, 15, or more inlet lines can be provided.
- Device 100 can also include a first filter 124 on the device's first side 126 and a second filter 128 on device's second side 130 . Although illustrated with only first filter 124 and second filter 128 , device 100 can include any number of filters that may be required. For example, device 100 can include three, four, five, six, seven, eight, nine, ten, eleven, twelve, 13, 14, 15, or more filters. In one embodiment, device 100 can include a separate/different filter for each input associated with device 100 .
- Hub 106 can be located before or after one or more filters described herein. In other embodiments, hub 106 can be placed before some filters and a second hub can be placed after the filters. Any number of hubs and filters can be used in any number of combinations.
- Hub 106 which can also be referred to as a manifold, can include two or more inlet lines and two or more outlet lines that enter a filter(s).
- a hub 106 can be illustrated as in FIG. 2A and FIG. 2B .
- Hub 106 includes a front side 202 and a back side 204 .
- hub 106 includes a wedge shape that has a larger surface area on front side 202 when compared to back side 204 .
- hub 106 can have other shapes such as a sphere, a cube, a cone, an ellipse, a spade, or the like.
- the internal channels of the hub can be built into a filter.
- different inlet lines can merge at a filter.
- the filter can help merge the inlet lines.
- the filters can be built into the hub.
- the lines running through the hub can include filters such that when the medications exit the hub, they have been filtered.
- Front side 202 can include at least two or more inlet lines.
- front side 202 includes a first inlet 206 which is fed by first inlet line 108 , a second inlet 208 which is fed by second inlet line 110 , a third inlet 210 which is fed by third inlet line 112 , a fourth inlet 212 which is fed by fourth inlet line 114 , a fifth inlet 214 which is fed by fifth inlet line 116 , a sixth inlet 216 which is fed by sixth inlet line 118 , a seventh inlet 218 which is fed by seventh inlet line 120 , and an eighth inlet 220 which is fed by eighth inlet line 122 .
- back side 204 includes a first outlet 222 and a second outlet 224 .
- other embodiments can include more outlets such as three, four, five, six, seven, eight, nine, ten, eleven, twelve, 13, 14, 15, or more outlets.
- hub 106 may only include one outlet.
- hub 106 can include first inlet 206 , second inlet 208 , third inlet 210 , fourth inlet 212 , fifth inlet 214 , sixth inlet 216 , seventh inlet 218 , and eighth inlet 220 .
- fourth inlet 212 and eighth inlet 220 are combined within hub 106 and fed to a first filter through first outlet 222 .
- first inlet 206 , second inlet 208 , third inlet 210 , fifth inlet 214 , sixth inlet 216 , and seventh inlet 218 are combined within hub 106 and fed to a second filter through second outlet 224 .
- Any combination of inlet and outlet numbers can be used to deliver medications through hub 106 .
- fourth inlet 212 and eighth inlet 220 are fed to first filter 124 and the remaining inlets can be fed into second filter 128 . In another embodiment, fourth inlet 212 and eighth inlet 220 are fed to a first filter and the remaining inlets can be fed into a second filter.
- Hub 106 can have different shapes depending on aesthetic and/or user needs.
- front side 202 can be curved, arched, pinched, spade-like, or triangular. Example configurations are illustrated in FIGS. 3A-E .
- front side 202 can be triangular with an apex point 302 . Having an apex point can allow for better placement of inlet ports when many inlets ports are in close proximity.
- front side 202 can simply be a flat surface.
- Filters used herein can also have any number of shapes.
- the shape of a filter can aid in the flow of a particular fluid through the filter.
- filters can have a substantially triangular shape.
- the filter can include channels and/or flow paths that run in the direction of flow.
- first side 132 can have a larger area than second side 134 to direct flow from hub 106 to outlet 102 in an efficient manner and/or to allow for a larger area on first side 132 to allow more filtering to occur when medications first reach the filter.
- filters can have other shapes such as square or substantially square, rectangular or substantially rectangular, circle or substantially circular, elliptical or substantially elliptical, trapezoidal or substantially trapezoidal, spade or substantially spade, or the like.
- Filters can also have different sized pores. Larger pore sizes can be used to filter substances such as lipid globules and other larger materials. Smaller pore sizes can be used to filter bacteria and/or microbes.
- a filter can have a 0.1 ⁇ m, 0.2 ⁇ m, 0.3 ⁇ m, 0.4 ⁇ m, 0.5 ⁇ m, 0.6 ⁇ m, 0.7 ⁇ m, 0.8 ⁇ m, 0.9 ⁇ m, 1.0 ⁇ m, 1.1 ⁇ m, 1.2 ⁇ m, 1.3 ⁇ m, 1.4 ⁇ m, 1.5 ⁇ m, 2 ⁇ m, 2.5 ⁇ m, 3 ⁇ m, 3.5 ⁇ m, 4 ⁇ m, 4.5 ⁇ m, 5 ⁇ m, 5.5 ⁇ m, 6 ⁇ m, or larger pore size.
- first filter 124 is a 0.2 ⁇ m filter and second filter 128 is a 5 ⁇ m filter.
- the filters can provide much larger pore sizes for different liquid substances such as, but not limited to blood or colloid products.
- pore sizes can be 50 ⁇ m, 100 ⁇ m, 150 ⁇ m, 200 ⁇ m, 250 ⁇ m, 300 ⁇ m, 350 ⁇ m, 400 ⁇ m, 450 ⁇ m, 500 ⁇ m, or larger, or between 50 ⁇ m and 300 ⁇ m, or between 100 ⁇ m and 500 ⁇ m.
- filters described herein can filter both particles and air.
- Filtering particles can prevent infusion of particulate matter than can disrupt blood flow into the vasculature of a patient.
- Filtering air in addition to particles can prevent infusion of air bubbles into the vasculature of a patient. Filtering air and/or particles can be particular importance for neonates and patient's with congenital heart disease.
- the filters described herein can be set up in series or can be set up in different channels that converge at or near outlet 102 . Further, at least two or more inlet lines 104 that converge at hub 106 can be fed to different filters depending on location of the inlet line, the inner diameter of the inlet line, or the like.
- any number of filters used in the described devices can feed into outlet 102 .
- the exit of filters described herein can feed into outlet 102 through a y-connector or junction 136 .
- Junction 136 can allow multiple filter exit lines to converge into outlet 102 with minimal dead space volume.
- Outlet 102 can be any connection type that can interface with a patient's IV tubing.
- outlet 102 can be a male luer lock.
- outlet 102 can rotate freely around the axis of the IV tubing without loosening the connection.
- device 100 can freely rotate around the axis of the IV tubing without loosening the luer lock connection.
- this luer lock can be called a spinning luer lock.
- a spinning luer lock or spinning luer connector can prevent the unintentional disconnection of the device from IV tubing as a result of internal pressure unwinding.
- An example spinning luer lock connector 400 is illustrated in FIGS. 4A-4F .
- Luer connector 400 includes a collar 402 that has a cup like shape that surrounds delivery protrusion 404 .
- Collar 402 can include internal threads 406 that can accept a female luer fitting that would exist on an IV inlet port.
- collar 402 can include within it a portion of a ratcheting mechanism including a gear 408 that runs around the internal circumference of collar 402 .
- Gear 408 can lock within it a pawl 410 associated with delivery protrusion 404 .
- An example pawl is illustrated in FIG. 4D where delivery protrusion 404 is illustrated without a collar.
- delivery protrusion 404 includes an open delivery outlet 412 at proximal end 414 and an O-ring or rib portion 416 that prevents a collar from progressing down delivery protrusion 404 from distal end 418 and seals the connection.
- Distal end 418 can be a continuous tube or be connected to device 100 directly.
- a device 100 As a device 100 is attached to a female luer connection 424 on an IV line 426 , screw portion 422 is twisted into internal threads 406 until luer connection 424 is tight and secure. Even when the luer connection is tight and secure, pawl 410 engages gear 408 thereby preventing disengagement of the luer lock without physically holding collar 402 to allow disengagement of the luer lock. However, without intentionally disengaging the luer lock, device 100 can spin freely around the axis of the IV line without coming loose.
- the hub can be situated within the body of the device itself or can be operably attached to the device's body. As illustrated in FIG. 5 , hub 502 is attached to device body 504 by one or more lines 506 . Such a manifold or hub can be referred to as external. In some embodiments, a device may have two, three, four, five, six, or more external hubs connected by a line. Line 506 can be permanently attached to both hub 502 and device body 504 or can be detachable from one or both of hub 502 or device body 504 .
- multiple external hubs can assist a user in spacing of syringes.
- eight different medications are to be delivered and eight closely situated syringes are difficult to navigate, they can be split between external manifolds to free up maneuvering space.
- the devices herein including body portions, encasements, hubs/manifolds, and the like can be formed of rigid polymers.
- Exemplary polymers include, but are not limited to polyurethanes, silicones, polyesters such as polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers, ethylene-co-vinylacetate, polybutylmethacrylate, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene
- hub 502 can include one or more inlets 508 along a horizontal line. Inlets can be situated in a horizontal line in order to provide space to attach the multiple syringes needed for a particular patient.
- inlets described herein can be a location where a tubing line enters a hub or manifold or can be attachment points for the syringes themselves. If the inlets on a hub or manifold are syringe attachment points, they can be spaced apart sufficient to allow adjacent syringes to be attached to the hub or manifold without obstruction.
- hub 502 in some embodiments could have a curved hub surface 510 to allow more spacing between adjacent inlets.
- each inlet line includes a connector for syringes, for example a needleless syringe connector.
- Needleless syringes can be used to prevent unintentional needle sticks and convenience for connecting and disconnecting the syringe from the presently described devices.
- Common luer connectors are not conducive to disinfecting prior to use. Although many luer connectors are sterile from the manufacturer, once opened in a medically relevant area, contamination can occur during device preparation and/or use.
- the needleless connectors used herein can have a surface that is conducive to scrubbing with disinfectant prior to use.
- Any needless syringe connector can be used, for example, compression fittings, luer lock connectors, BD Q-SYTE® Luer Access Split Septum (Becton, Dickinson and Company, Franklin Lakes, N.J.), INTERLINK® Needleless IV Access Devices (Becton, Dickinson and Company, Franklin Lakes, N.J.), CARESITE® Luer Access Device (B. Braun Medical, Inc., Bethlehem, Pa.), INVISION-PLUS® IV Connector with or without Neutral Advantage Technology Rymed Technologies, LLC, Franklin Tenn.), SAFELINE® Split Septum Needleless Connector (B.
- the inlet lines described herein can each include an anti-reflux valve to prevent back flow of medicament into the syringe once it has been delivered to the inlet line.
- Any anti-reflux valve can be used.
- anti-reflux valves can be included within the needleless syringe connector. In other embodiments, the anti-reflux valves can be independent to the connectors.
- the outlet lines described herein can include an anti-reflux valve to prevent back flow of medicament into the device once it has been delivered to the patient's IV line. Any anti-reflux valve can be used. In some embodiments, anti-reflux valves can be included within the connector used to attach the device to the patient's IV line. In other embodiments, the anti-reflux valves can be independent to the connector.
- Inlet port tubing described herein can be tubing with a minimal internal volume such as having the smallest internal diameter.
- tubing can be microtubing.
- the tubing can have the smallest internal diameter needed, different internal diameter tubing can be used as appropriate for a particular medication being delivered through an inlet. For example, a more viscous material may require tubing with a larger internal diameter than an aqueous based medication.
- channels though hubs, y-connectors, and the like can have the smallest internal diameter required for delivery of medications.
- Tubing and channels described can have internal diameters of less than about 0.05 mm, less than about 0.1 mm, less than about 0.2 mm, less than about 0.3 mm, less than about 0.4 mm, less than about 0.5 mm, less than about 0.6 mm, less than about 0.7 mm, less than about 0.8 mm, less than about 0.9 mm, less than about 1 mm, between about 0.05 mm and about 0.5 mm, or between about 0.05 mm and about 0.1 mm.
- Inlet tubing lengths can be less than about 15 cm, less than about 14 cm, less than about 13 cm, less than about 12 cm, less than about 11 cm, less than about 10 cm, less than about 9 cm, less than about 8 cm, less than about 7 cm, less than about 6 cm, less than about 5 cm, less than about 4 cm, less than about 3 cm, or less than about 2 cm.
- microtubing can be used, in some embodiments, macrotubing can also be used. Larger tubing may be desired if multiple medications are being pushed through the filters or if macrotubing is required for a more viscous medication. Thus, if microtubing is used for some inlets and macrotubing is used for other inlets, the device may include macrotubing at a device outlet in order to accommodate the more viscous medications.
- inlet ports/connectors can be configured for single use.
- an inlet connector can include single direction locking configurations or connections that lock and break into that configuration preventing further use of the connection after its initial use.
- This single use inlet connection prevents subsequent use of a device as described herein. Further, this single use inlet connection prevents cross-contamination of medications in delivery syringes that may subsequently be connected to an inlet that was not single use.
- inlets, inlet lines, and/or inlet ports can be color coded. Color coding can assist a user in identifying a particular feature of the device and reduce error in device usage.
- color coding can be used to identify a particular inlet's affiliation with a filter(s).
- devices herein can have multiple different filters with different inlets feeding different filter types/sizes, different inlets, inlet lines, and/or inlet ports can be color coded to represent to a user which inlets feed which filter.
- color coding can be used to match particular medications with particular inlets.
- color coding can be used to identify a particular order of medication delivery.
- syringes can be color coded to match particular inlet colors. Such color matching can ensure that medications are delivered throughout a predetermined inlet using the visual color cue.
- inlets can include particular syringe locking mechanisms that match syringe locking mechanisms in order to prevent miss-attachment of a medication to an inappropriate inlet.
- inlets feeding a larger pore size filter can include one type luer connection and inlets feeding a smaller pore size filter can include a different luer connection, wherein the two luer connections are not interchangeable.
- Such locking mechanism usage can ensure that medications are delivered throughout a predetermined filter by preventing attachment of a medication to an inappropriate filter.
- device 100 as illustrated in FIG. 6 is assembled with syringes attached.
- Device 100 includes a body portion that includes filters as described herein.
- Hub 106 includes first inlet line 108 with a first syringe 606 attached to first connector 608 , second inlet line 110 with a second syringe 614 attached to second connector 616 , third inlet line 112 with a third syringe 618 attached to third connector 620 , fourth inlet line 114 with a fourth syringe 626 attached to fourth connector 628 , fifth inlet line 116 with a fifth syringe 602 attached to fifth connector 604 , sixth inlet line 118 with a sixth syringe 610 attached to fifth connector 612 , seventh inlet line 120 with a seventh syringe 622 attached to seventh connector 624 , and eighth inlet line 122 with an eighth syringe 630 attached to eighth connector 632 . Because syringes can be attached simultaneously, there is
- the devices described herein can be sterilized using any common sterilization technique without substantially degrading the device.
- the sterilization method can be autoclaving, gamma radiation, or ethylene oxide.
- the devices can be sterilized before or after packaging.
- devices as described herein can be provided as kits for use.
- Any kit can include an appropriate packaging and instructions for use.
- Other information can be provided with the kits such as device dimensions, filter specifics, regulatory clearances/approvals, company information, marketing materials, and the like.
- kits can include a device such as device 100 in an appropriate packaging with at least instructions for use.
- a kit can include a device such as device 100 in an appropriate packaging with a number of syringes that matches the number of inlets allowing only one syringe use per inlet.
- the kit can also include at least instructions for use.
- a kit can include a device such as device 100 in an appropriate packaging with colored inlet lines that represent what lines go to what filters.
- the kit can also include at least instructions for use.
- a kit can include a device such as device 100 in an appropriate packaging with colored inlet lines. A number of syringes color coded with the inlet lines can also be included. The kit can also include at least instructions for use.
- a kit can include a device such as device 100 including pre-filled syringes with medications directly from the pharmacy already attached to the device using a locked connector that cannot be removed from the device.
- the kit can also include at least instructions for use.
- a kit can include a device such as device 100 with colored inlet lines. A number of syringes color coded with the inlet lines can also be included that have been pre-filled by the pharmacy. The kit can also include at least instructions for use.
- a device as described herein for example device 100 or device 600 can be unpackaged and its outlet port hooked into a patient's IV line using a luer style connector. Other connectors can also be used. Then, a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. Then, a provider delivers combinations of medications as needed by a patient.
- This method allows all the medications or at least a majority of the medication syringes to be attached to the device and hence the IV line without the need to scrub a port to attach a separate syringe when a time sensitive medication has already been administered to a patient.
- a device as described herein for example device 100 or device 600 can be unpackaged. Then, a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. The device's outlet port is then hooked into a patient's IV line. Then, a physician, advanced practice nurse, nurse, and/or provider can deliver combinations of medications as needed by a patient.
- a device as described herein for example device 100 or device 600 can be unpackaged and its outlet port hooked into a patient's IV line. Then, a first inlet port with a particular color is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe having a matching color is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. Then, a physician, advanced practice nurse, nurse, and/or provider delivers combinations of medications as needed by a patient.
- a device as described herein for example device 100 or device 600 can be unpackaged. Then, a first specifically colored inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe of the matching color is attached to the scrubbed port. This process is repeated using matching syringes and ports until all ports have been sterilized and syringes attached. The device's outlet port is then hooked into a patient's IV line. Then, a physician, advanced practice nurse, nurse, and/or provider can deliver combinations of medications as needed by a patient.
- the devices described herein can also interface with automated instruments.
- the devices can interface between an automated instrument and a patient's IV line.
- device inlets can be connected to automated instrument outlets after appropriate port swabbing and the outlet of the device can be connected to the patient's IV line again after appropriate swabbing.
- the instrument can then deliver varying amounts of medications through the device and into the patient's IV line.
- the devices described herein can also be included within an automated instrument and output contents to a patient's IV line.
- device inlets can be connected within an automated instrument and the outlet of the device can be connected to the patient's IV line again after appropriate swabbing when the automated instrument is brought to a patient.
- the instrument can then deliver varying amounts of medications through the device and into the patient's IV line.
- two or more devices can be coupled together to add additional ports to a system.
- a device with two inlets can have an inlet coupled to an outlet port of another device with two inlets.
- any number of additional devices can be added and chained together as appropriate.
- a desired IV inlet port Prior to surgery in the operating room, a desired IV inlet port is aseptically prepared and/or scrubbed for at least 15 seconds to thoroughly disinfect the port. Then, a device as described herein is removed from its sterile packaging and attached to the IV inlet port. A patient who is prepped for joint replacement then enters the operating room.
- a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an anesthesia such as propofol is attached to the first scrubbed port.
- a second inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an antibiotic such as cefazolin is attached to the second scrubbed port.
- a third inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a local anesthesia such as lidocaine is attached to the third scrubbed port.
- a fourth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a neuromuscular blocking agent such as rocuronium is attached to the fourth scrubbed port.
- a fifth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an anxiolytic/amnesic such as midazolam is attached to the fifth scrubbed port.
- a sixth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a narcotic such as fentanyl is attached to the sixth scrubbed port.
- a seventh inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including back up supply of anesthetic such as propofol attached to the seventh scrubbed port.
- An eighth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a blood pressure support medication such as ephedrine is attached to the eighth scrubbed port.
- the eighth port can instead be loaded with an anti-nausea medication such as zofran.
- a device with nine inlet ports can be provided.
- the provider can turn the device including all syringes over without risking loosening of the outlet port to the IV inlet because of the rotating connector on the device.
- a provider delivers combinations of medications as needed by a patient without the need to remove and replace medications and waste time aseptically preparing and/or scrubbing ports once anesthesia has been initialized and anesthetizes the patient for surgery with a minimized risk of infection or patient risk.
- a patient is rushed for a crash caesarean section under general anesthesia.
- the provider places an order to the pharmacy for a cocktail of medications to anesthetize the patient for surgery.
- a device as described herein with four syringes already connected is delivered to the operating room prior to the patient's arrival to the operating room.
- a first inlet port includes a sterile medication syringe including an anesthesia such as propofol; a second inlet port includes a sterile medication syringe including an antibiotic such as cefazolin; a third inlet port includes a sterile medication syringe including a narcotic such as fentanyl; a fourth inlet port includes a sterile medication syringe including a neuromuscular blocking agent such as succinylcholine.
- the desired IV inlet port is aseptically prepared and/or scrubbed for at least 15 seconds to thoroughly disinfect the port. Then, the device is attached to the disinfected IV inlet port. The provider can turn the device including all syringes over without risking loosening of the outlet port to the IV inlet because of the rotating connector on the device.
- a provider delivers combinations of medications as needed by a patient without the need to remove and replace medications and waste time aseptically preparing and/or scrubbing ports once anesthesia has been initialized and anesthetizes the patient for surgery with a minimized risk of infection or patient risk.
- Procedure related sedation which can occur in multiple hospital settings both in the emergency department, intensive care, and/or locations where anesthesia is administered for patients who require deep sedation only for the length of a procedure.
- Medications such as propofol can be combined with ketamine, etomidate, dexmeditomidine, fentanyl, midazalam, lidocaine or saline.
- Providing brief, titratable, deep sedation can be delivered by programmable automated instruments or directly by the provider.
Abstract
Described herein are devices for delivering at least two different medications without requiring disconnections and reconnections of medication syringes. In some embodiments, the devices can accommodate at least two syringes simultaneously. In some embodiments, the device can be torqued while delivering the at least two different medications without loosening the outlet port from an intravenous line the device is hooked up to.
Description
- This application is a divisional of U.S. patent application Ser. No. 15/156,086, filed May 16, 2016, which claims the benefit of U.S. provisional patent application No. 62/175,941 filed on Jun. 15, 2015, the entire disclosures of which are incorporated herein by reference in their entirety.
- The present invention relates generally to multi-port, multi-formulation introduction devices.
- Described herein generally are multi-port, multi-formulation intravenous (IV) delivery devices that can allow a physician, advanced practice nurse, nurse, provider, or the like to deliver several time sensitive formulations such as medications while reducing and/or eliminating chances of infection, particle infusion, air infusion, or a combination thereof.
- In one embodiment, devices for delivering at least two different medications are described. The devices can deliver two, three, four, five, six, seven, eight, nine, ten, or more medications. The devices can comprise a body section including at least two inlet ports. In some embodiments, at least one of the at least two inlet ports includes an anti-reflux valve and is operably connected to a first filter. In certain embodiments, one of at least two inlet ports includes an anti-reflux valve and is operably connected to a first filter and another inlet port of the at least two inlet ports includes an anti-reflux valve and is operably connected to a second filter. The devices can further include a rotating outlet port joined to the first filter and the second filter by a y-connector and configured to connect to an intravenous line. In some embodiments, the outlet port can be a fixed luer lock. In some embodiments, the devices can be torqued, spun, and/or rotated while delivering the at least two different medications without loosening the outlet port from the intravenous line.
- In some embodiments, the first filter can be a 0.2 μm filter and the second filter can be a 5 μm filter. In some embodiments, at least one inlet port flows into the first filter and at least one inlet port flows into the second filter.
- The at least two inlet ports described can be scrubbable inlet ports. In other embodiments, the devices can include two inlet ports. In other embodiments, the devices can include four or eight or more inlet ports.
- The devices described can have a minimal amount of dead space within the devices and/or the device lines.
- In some embodiments, the rotating outlet port includes a gear and a pawl that can allow rotation without loosening the outlet port from the intravenous line.
- In other embodiments, the outlet port on the devices can be a male luer lock. The male luer lock can be a spinning male luer lock. In some embodiments, the male luer lock can also be a fixed luer lock that does not spin.
- Methods are also descried for using the herein described devices. Methods can include methods of delivering at least two different time sensitive medications. These methods can include delivering at least a first medication in a first syringe and a second medication in a second syringe through a device into an intravenous line without disconnecting the first syringe or the second syringe.
- The medications delivered using the described methods can be anesthetics. In some embodiments, an anesthetic can be propofol.
- The methods can utilize a device that comprises a body section including at least two inlet ports. In some embodiments, at least one of the at least two inlet ports includes an anti-reflux valve and operably connected to a first filter and another inlet port of the least two at least one additional of the at least eight inlet ports includes an anti-reflux valve and operably connected to a second filter.
- The methods can further comprise delivering at least a third medication in a third syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, or the third syringe.
- Further, the methods can include delivering at least a fourth medication in a fourth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, or the fourth syringe.
- Further still, the methods can include delivering at least a fifth medication in a fifth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, or the fifth syringe.
- In one embodiment, the methods comprise delivering at least a third medication in a third syringe, a fourth medication in a fourth syringe, a fifth medication in a fifth syringe, a sixth medication in a sixth syringe, a seventh medication in a seventh syringe, and an eighth medication in an eighth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, the fifth syringe, the sixth syringe, the seventh syringe, or the eighth syringe.
-
FIG. 1 illustrates an example embodiment of a device as described herein. -
FIG. 2A is a front perspective view of a hub as described herein.FIG. 2B is a back perspective view of a hub as described herein. -
FIG. 3A is a back view of a hub as described herein.FIG. 3B is a side view of an exemplary hub.FIG. 3C is a front view of the hub inFIG. 3B .FIG. 3D is a side view of another exemplary hub.FIG. 3E is a front view of the hub inFIG. 3D . -
FIG. 4A illustrates an assembly of a spinning connection as described herein. -
FIG. 4B illustrates the male connection ofFIG. 4A .FIG. 4C illustrates the female connection ofFIG. 4A .FIG. 4D illustrates a component of the assembly inFIG. 4A . -
FIG. 4E is a cross-section as indicated inFIG. 4A .FIG. 4F is another cross-section as indicated inFIG. 4A . -
FIG. 5 illustrates an embodiment where a hub is distant to the body of the device. -
FIG. 6 is an illustration of a device assembled with eight syringes. - Described herein generally are intravenous (IV) infusion devices that can reduce and/or eliminate chances of infection, particle infusion, air infusion, or a combination thereof when used as directed. The devices can alleviate the need for IV port aseptic preparing and/or scrubbing between time sensitive medication deliveries.
- In some embodiments, the multi-lumen devices can be anesthesia induction devices. Anesthesia delivery can be extremely time sensitive, and delivering anesthesia with the described devices can reduce the time burden on medication delivery. These devices can be scrubbable, for example, at any and all introduction ports or exit ports in the devices. Further, the devices can be self-priming meaning that air and particulates can be removed from solution(s) being delivered through the device.
- Infections that patients develop while they are receiving care in a healthcare setting for another condition are termed healthcare-associated infections (HAIs). HAIs occur throughout the world, affecting hundreds of millions of patients each year. These infections are not only costly to individuals and health care systems; they can significantly increase morbidity and mortality. Seriously ill patients are particularly vulnerable to serious complications due to HAIs, likely due to factors such as progressively more invasive medical technology and complex medical procedures, increasing immunocompromised status and elderly age, and the rising incidence of antimicrobial resistance. However, many HAIs are preventable when evidence-based guidelines are incorporated into patient care.
- Use of vascular catheters is common in both inpatient and outpatient care. In the United States, it is estimated that almost 300 million catheters are used each year; nearly 3 million of these are central venous catheters (CVCs), also known as central lines. Central venous catheters play an integral role in modern health care, allowing for the administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as providing hemodialysis access and hemodynamic monitoring. However, their use is associated with a risk of bloodstream infection caused by microorganisms colonizing the external and/or internal surface of the device or the fluid pathway when the device is inserted or in the course of its use. Central venous catheters are the most frequent cause of healthcare-associated bloodstream infections, called central line-associated bloodstream infections (CLABSI).
- An estimated 330,000 CLABSIs occur each year in the United States, 80,000 of those occur in the intensive care unit (ICU). CLABSIs are serious but often preventable infections when evidence-based guidelines are followed for the insertion and maintenance of central lines.
- As with other HAIs, CLABSIs also increase the cost of health care and prolonged hospital stays by up to three weeks. Non-inflation-adjusted costs associated with CLABSIs have varied from $3,700 per infection to $36,441 per infection. A recent CDC estimate set the cost of each CLABSI at $16,550.
- For many years most harm that occurred in health care was considered inevitable; fortunately, that way of thinking has been replaced in the developed world by one that categorizes harm as largely preventable. The progress that has been made in recent years in reducing CLABSIs points to their preventability, as illustrated by the following examples:
- Umscheid et al. estimated that as many as 65% to 70% of CLABSIs may be preventable with the implementation of evidence-based strategies (Infection Control Hospital Epidemiology, 2011; 32(2): 101-114).
- Pronovost and colleagues from the Johns Hopkins Quality and Safety Research Group demonstrated, initially in 103 ICUs in Michigan, that increased use of evidence-based interventions and an improved culture of patient safety can prevent CLABSIs. At the end of the 36-month study period, there was a 60% overall reduction in the baseline CLABSI rate. As a result, $200 million and an estimated 2,000 lives were saved.
- Overall, the high morbidity and mortality associated with CLABSI, improved understanding of its pathogenesis and preventability, and the growing unwillingness of patients, payers, and patient advocates to look at HAIs as an acceptable risk has led to the emergence of a “zero tolerance” mind-set—an emphasis that organizations set the goal at eliminating HAIs rather than being comfortable with meeting national or local averages. Employing relatively simple evidence-based practices to reduce, if not eliminate, CLABSIs appears to be within the reach of even resource-limited settings. Within this framework, HAIs—and CLABSIs in particular—are more and more being viewed as “preventable” events.
- As such, there is a need in the art for intravenous (IV) infusion devices that can reduce and/or eliminate chances of infection. Devices that can reduce and/or eliminate infection are disclosed herein.
- Rapid sequence induction, also described as rapid sequence intubation (RSI), is an advanced airway management medical procedure used to achieve tracheal intubation under the induction of anesthesia in patients who are at high risk of pulmonary aspiration. Rapid sequence intubation refers to the pharmacologically induced sedation and neuromuscular paralysis prior to intubation of the trachea. The technique is a quicker form of the process normally used to induce general anesthesia.
- Rapid sequence induction involves pre-filling the patient's lungs with a high concentration of oxygen gas, followed by administering rapid-onset hypnotic and neuromuscular-blocking drugs that induce prompt unconsciousness and paralysis, allowing tracheal intubation with minimal delay. Unlike other methods of induction, no artificial ventilation is provided from the time that drugs are administered until after intubation has been achieved; this minimizes insufflation of air into the stomach, which might otherwise lead to regurgitation. But also requires rapid airway management and intervention as the patient is apneic and will begin to develop oxygen-hemoglobin desaturation.
- Rapid sequence induction is used where general anesthesia must be induced before the patient has had time to fast long enough to empty the stomach; where the patient has a medical condition that makes aspiration more likely during induction of anesthesia, regardless of how long they have fasted (such as gastro-esophageal reflux disease); or where the patient has become unable to control their own airway even before anesthesia (such as with the critically ill or after a traumatic brain injury).
- Typically RSI is initiated in an Emergency Room, Operating Room and/or the Intensive Care Unit. It is also utilized outside of these typical hospital settings and can occur in the Emergency Medical Response settings within the scope of the practice of paramedics, firefighters, and other healthcare professionals.
- The induction drugs preferentially used in RSI have short durations of action, wearing off after only minutes. This confers a degree of fault tolerance on the procedure when it is used in elective or semi-elective settings: if intubation is unsuccessful, and if the clinical condition allows it, the procedure may be abandoned and the patient should regain the ability to protect their own airway sooner than would be the case under routine methods of induction. Conversely, in emergency settings where the patient's condition does not allow for them to be woken up immediately, a failed RSI places them at very high risk for respiratory compromise.
- Commonly used medications during a rapid sequence intubation include, but are not limited to, sedatives such as midazolam, ketamine, fentanyl, propofol, and etomidate, paralytics such as succinylcholine, rocuronium, vecuronium, and other medications such as atropine for patients where bradycardia is a concern, and ephedrine where hypotension may occur secondary to the sedating drugs.
- Pretreatment for RSI consists of the medications given to specific groups of high-risk patients minutes before the paralysis stage with the aim of protecting the patient from the adverse effects of introducing the laryngoscope and endotracheal tube. Intubation causes increased sympathetic activity, an increase in intracranial pressure and bronchospasm. Patients with reactive airway disease, increased intracranial pressure, or cardiovascular disease may benefit from pretreatment.
- Two common medications used in the pretreatment of RSI include, but are not limited to, lidocaine and atropine.
- Lidocaine has the ability to suppress the cough reflex which in turn may mitigate increased intracranial pressure. For this reason lidocaine is commonly used as a pretreatment for trauma patients who are suspected of already having an increase in intracranial pressure. The typical IV dose is given three minutes prior to intubation. Lidocaine is also theorized to blunt a rise in intracranial pressure during laryngoscopy, although this remains controversial and its use varies greatly.
- Atropine, as a parasympathetic blocker, may also be used as a premedication agent in pediatrics to prevent bradycardia caused by hypoxia, laryngoscopy, and succinylcholine. Atropine may be used to prevent a reflex bradycardia from vagal stimulation during laryngoscopy, especially in young children and infants. Despite their common use, such adjunctive medications have not been demonstrated to improve outcomes.
- With standard intravenous induction of general anesthesia, the patient typically receives an opioid, and then a hypnotic medication. Generally the patient will be manually ventilated for a short period of time before a neuromuscular blocking agent is administered and the patient is intubated.
- During rapid sequence induction, the person still receives an IV opioid. However, the difference lies in the fact that the induction drug and neuromuscular blocking agent are administered in rapid succession with no time allowed for manual ventilation.
- Commonly used hypnotics include thiopental, propofol and etomidate. Commonly used neuromuscular blocking agents used include succinylcholine and rocuronium. The neuromuscular blocking agents paralyze all of the skeletal muscles, most notably and importantly in the oropharynx, larynx, and diaphragm.
- Opioids such as Fentanyl may be given to attenuate the responses to the intubation process (accelerated heart rate and increased intracranial pressure). This is supposed to have advantages in patients with ischemic heart disease and those with brain injury (e.g. after traumatic brain injury or stroke).
- One important difference between RSI and routine tracheal intubation is that the practitioner does not typically manually assist the ventilation of the lungs after the onset of general anesthesia and cessation of breathing, until the trachea has been intubated and the cuff has been inflated.
- Human Factor Engineering (HFE) is a critical stage in medical device development. The FDA has provided guidance regarding HFE as a standard during the regulatory process. Product design plays an important role in usability, and clinical effectiveness ensuring safety while reducing human error. Estimates suggest that the FDA receives an average of 100,000 medical device incident reports per year. More than a third of those incident reports are due to user error. Furthermore, it is estimated that more than 44% of product recalls are due to design errors. A set of product design specifications (PDS) have been developed which include HFE and aim to improve the devices in the art by reducing risk of device use error, outlining proper device use, reducing need for training or user manual reference, providing safe connections to and between other products, improving user experience, detailing proper user handling, meeting ergonomic standards.
- Human factor engineering is being implemented by the devices described herein through product enhancement to the following attributes: design, such as but not limited to, an ergonomic mold for handheld use and versatile compatibility, specific IV tubing ID/OD improving clinical effectiveness, specific IV tubing length adjusted for syringe accessibility, and luer collar distance from device body addressing ease of handling, materials such as but not limited to, clear PVC for fluid flow visualization, medical grade PVC for sterile applications, specified filter housing dimensions improving clinical effectiveness, specified filter membrane addressing removal of specific foreign bodies, and add on products such as, but not limited to, color coded IV tubing for fluid identification, color coded IV connectors for fluid identification, and molding, assembly and packaging by a single manufacturer.
- In some embodiments, in addition to the devices being self-priming, they can also produce low waste volume. In other words, the devices can function with minimal dead volume thus providing more accurate delivery of solution(s) through the devices.
- The devices described herein can also filter solution(s) that are introduced through the devices. In some embodiments, the devices have one filter. In other embodiments, the devices have more than one filter.
- By providing one or more of the above features of scrubability, self-priming, filtering, and minimal dead volume delivery, the presently described devices can prevent health care workers' inadvertent IV infusion of air, microorganisms, endotoxins, particulate matter, and/or lipid emboli into a patient.
- In some embodiments, the devices described herein can be used to deliver solution(s), such as formulations or medications to a patient. The patient can be a mammal such as a human, cat, dog, horse, cow, bull, goat, bison, or the like. When used with/for patients, the devices can meet the highest safety standards imposed by local, regional, or governmental regulations for introduction and maintenance of formulation delivery.
- Further, because the devices can include at least two inlet ports, the devices can eliminate a need for multiple connections during introduction of formulations into a patient. Therefore, the devices can reduce overall time and the potential for contamination of the formulations during delivery. In other words, the devices can provide safe, efficient and reliable methods to perform multi-formulation delivery. In one embodiment, the devices described can assist in preventing healthcare-associated infections (HAI) which have become a growing problem in therapeutic and hospital settings.
- Currently, no device exists that addresses all potential risks associated with administering IV formulations and/or medications to patients. In particular, no device exists that addresses all potential risks associated with administering IV anesthesia to patients. With the delivery of anesthesia, time is a critical factor in the delivery of different anesthetic medications and/or medications subsequent to an anesthetic medication to ensure the patient's survival.
- The devices and systems described herein can include the following benefits: be sterile when opened for use, be preassembled for on demand delivery of medications, be self-priming, be closed to ambient air flow, each port/hub/cap connector can possess an ability to be aseptically prepared and/or scrubbed and/or sterilized prior to connection for access of IV medications, can filter air, can filter particulate matter, can filter lipids, can filter microorganisms and endotoxins, can limit connection to only one access of the patient's IV tubing, can include one-way/anti-reflux valves to prevent retrograde IV fluid or blood flow, can include the ability to securely isolate chosen medications dedicated to one patient, can be easy to use during a single provider rapid sequence induction of medication, and/or can include minimal dead space within the fluid pathways.
- The devices described herein can include various combinations of cap/cap connectors, female lure locks, anti-reflux valves, micro-tubing, multi-lumen manifold, low volume filters, Y-connector, macro-tubing, and easy to use male lure lock(s). The systems can be customizable prior to manufacturing and individually distributed to healthcare providers as a one-time use device.
- Further, the devices can improve patient safety and/or streamline the process of administering IV medications, such as anesthesia, through the reduction in errors of contaminations and infections of the patient's blood stream by eliminating inadvertent infusions of particulates and securely isolating IV medications for the use by one patient. In one embodiment, the devices can employ the highest level of infection prevention standards set by the CDC (Centers for Disease Control and Prevention), TJC (The Joint Commission), SHEA (The Society for Healthcare Epidemiology of America), World Health Organization (WHO), National Institute of Health (NIH), United States Department of Health and Human Services (HHS), European Centre for Disease Prevention and Control, Centers for Medicare, and/or Medicaid Services.
- The devices can also reduce time associated with medication introduction by eliminating multiple connections and disconnections of medication syringes during the standard rapid introduction sequence.
- For example, the CDC in 2011 provided the Guidelines for the Prevention of Intravascular Catheter-Related Infections. These guidelines have been developed for persons responsible for surveillance and control of infections in hospital and states at page 54: “[m]inimize contamination risk by scrubbing the access port with an appropriate antiseptic (chlorhexidine, povidone iodine, an iodophor, or 70% alcohol) and accessing the port only with sterile devices.”
- Likewise, the TJC recommends that a medical provider “scrub the hub you are accessing every time you use it” (CLABSI (central line associated blood stream infections) Toolkit: Valve Disinfection Guidance, Mar. 21, 2014). Scrubbing a hub every single time it is being accessed is a near impossible task when time sensitive medications, such as anesthesia, are being delivered.
- Further still, SHEA has provided a 2014 Compendium which is a concise distillation of current guidelines for the prevention of HAIs that brings together recommendations from respected sources in a format suited to implementation in the clinical setting. It also includes metrics and indicators of success for implementation. The Compendium states that “[i]f CLABSI surveillance or other risk assessments suggest that there are ongoing opportunities for improvement, hospitals should then consider adopting some or all of the prevention approaches listed as special approaches”. In some embodiments, the devices described herein can be categorized as a special approach under the 2014 Compendium.
- Port scrubbing is a CDC recommendation, the TJC states mandatory port scrubbing prior to administration of IV medications, and SHEA considers “special approaches” for additional prevention of blood stream infections. The present devices can meet all these needs and more.
- Port Scrubbing is generally considered to require at least 15 seconds of scrubbing an access port with an appropriate antiseptic prior to the administration of every IV medication. Appropriate anesthetics can be, but are not limited to, chlohexadine, providone iodine, an iodophor, or 70% alcohol.
- The devices described herein can prevent and/or reduce the chance of a blood stream infection (BSI) and/or HAIs. Blood stream infections and/or HAIs can many times be associated with the contamination of IV ports and IV junctional connections during IV medication and IV fluid administration. Blood stream infections and/or HAIs are a great risk for patients that require IV medication therapy. Over 500,000 catheter-related BSIs occur in the United States every year, costing the United States healthcare system over $10 billion annually.
- A patient's blood stream is a dynamic and sterile environment that, once contaminated, can pose multiple life threatening problems. Contaminations of a patient's blood stream can occur via both endogenous (e.g., patient's skin flora) and extrinsic (e.g., health care workers' hands) exposure to the medication fluid pathways. The most vulnerable populations are the immune compromised patients who include, but are not limited to, neonates, elderly, critically ill, hematology patients, oncology patients, transplant patients, and the like. Also vulnerable are those patients with an indwelling or implanted medical device including, but not limited to, central venous catheters (CVC), prosthetic joint, shunts, hardware, and the like.
- Blood stream infections carry a high percentage of mortality for the vulnerable populations. It has been reported that BSIs have a reported mortality up to 25%. Blood Stream Infections can lead to endocarditis, osteomyelitis, sepsis, stroke, infected heart valves, infected joints, infected implanted devices and other life threatening illnesses. The presently described devices can reduce a patient's risk of infection by, in part, preventing connections and disconnections without proper or recommended port scrubbing.
- Every IV medication administration can also potentially allow embolic air and particles into the patient's blood stream. This occurs via the fluid pathway by way of IV injection ports. The present devices can eliminate or substantially reduce embolic air introduction into an IV line.
- Lipid based medication also poses a risk of inadvertent infusion of large globule molecules, which can lodge in the pulmonary vasculature compromising respiratory function. The present devices can eliminate or substantially reduce globule introduction into an IV line.
- In the area of delivery of anesthesia through an IV, healthcare providers currently prepare and utilize multiple sterile, single use syringes and individually connect and disconnect them to and from the patients' IV tubing access ports. Occasionally, a healthcare provider will attach multiple syringes to a small manifold or several injection ports on a patient's IV tubing prior to the induction of anesthesia. However, the sequence of administering multiple medications during the induction of anesthesia limits the provider's ability to properly clean between medication administrations and limits the provider's ability to keep the access ports, syringe tips and medications sterile for future medication administration, especially during and after the sequence of the induction of anesthesia. These risks occur in both the adult and pediatric populations in all settings in anesthesia.
- The current techniques risk inadvertent infusion of particulate matter, air and lipid emboli, microorganisms and endotoxins that can be introduced to the patient's bloodstream via the inadvertent contamination of the IV medication, medication syringe, cap connector or access point connection. The probability of contamination dramatically increases with each IV access connection performed by a healthcare provider. The average induction and maintenance of anesthesia requires a range of 2-10 different IV medications, each requiring repeated connections and reconnections of separate syringes to and from the patient's IV tubing in a rapid sequence prior to initiation of airway management.
- The devices described herein can provide the highest-grade standards for all IV infusions. The devices described herein can also provide the safest and/or most efficient approach to the administration of IV anesthesia, especially during the induction sequence of multiple medications of which timed delivery is critical and 15 second scrub times for each port may not be possible without compromising the patient's safety.
- Medications can be loaded into separate syringes for delivery to a patient using the present devices without constant connections and disconnections. Medications that can be delivered using the presently described devices include, but are not limited to, anesthesia, antibiotics, saline, muscle relaxing agents, neuromusclar blocking agents, anxiolytics/amnesics, narcotics, stimulants, anti-nausea medications, chemotherapeutics, antimicrobials, steroids, non-steroidal anti-inflammatories, nerve blocks, vitamins, gene therapies, nutrients, emergency medications such as heart rate and blood pressure support medications, and the like.
- In one embodiment, the medications can be anesthetics and the medications that support delivery of anesthesia. Anesthesia can include propofol and/or lidocaine. Antibiotics can include cefazolin which may require a saline flush. Saline can also be used to flush the device lines described herein. In one embodiment, a saline flush may be recommend to ensure the medications are delivered to the patient and are not retained within the device. Neuromuscular blocking agents can include rocuronium. Anxiolytics/amnesics can include midazolam. Narcotics can include fentanyl. Emergency medications can include phenylephrine, ephedrine, epinephrine and vasopressin. Anti-nausea medications can include ondansetron and dexamethasone.
- The enumerated medications are presented as non-limiting medications. Each anesthetic poses its unique challenges, and therefore the selection of medications represents the needs or potential needs of the patient and the type of surgery's anesthesia requirements. Some anesthesia cases require less than the categories/medications listed and some require more. In some embodiments, the combinations of medications required for anesthesia for a patient can be as few as two and as many as ten or more to complete an anesthetic.
- Further, the delivery of the anesthesia can be extremely time sensitive. The devices described herein can assist and/or solve problems that exist with time sensitive delivery of the medications for anesthesia. For example if eight different medications are being delivered in an anesthetic treatment, including 15 second port scrub times between medications, two minutes would be spent simply cleaning the port between each medication delivery which does not account for the actual time for delivery. For example, if propofol is the first medication delivered, there is simply not sufficient time to scrub delivery ports and deliver subsequent medications without putting a patient at risk. Thus, often ports are not aseptically prepared and/or scrubbed and contaminations and patient infections can occur. Further, because infection is being introduced directly into the bloodstream, time to sufficiently disinfect inlet ports is absolutely critical. The present devices solve these and other problems. The device, in combination with positive pressure, continuous flow infusion pump, is intended to deliver fixed doses of medication upon demand by the patient or healthcare provider.
- An example device,
device 100, is illustrated inFIG. 1 .Device 100 can include anoutlet 102.Outlet 102 can be configured to be connected to an IV line or other introduction line.Outlet 102 can be of a standard line connector or can include anti-torqueing or spinning connectors as will be described in greater detail herein. In other embodiments, outlet can be a standard, fixed luer connection. In one embodiment,device 100 is for single patient use. -
Device 100 can include at least two ormore inlet lines 104 that interface or otherwise meet athub 106. Each of the at least two ormore inlet lines 104 can be the same or different size line. In one embodiment herein,device 100 includes afirst inlet line 108, asecond inlet line 110, athird inlet line 112, afourth inlet line 114, afifth inlet line 116, asixth inlet line 118, aseventh inlet line 120, and aneighth inlet line 122. More than eight inlet lines can be included indevice 100. For example, nine, ten, eleven, twelve, 13, 14, 15, or more inlet lines can be provided. -
Device 100 can also include afirst filter 124 on the device'sfirst side 126 and asecond filter 128 on device'ssecond side 130. Although illustrated with onlyfirst filter 124 andsecond filter 128,device 100 can include any number of filters that may be required. For example,device 100 can include three, four, five, six, seven, eight, nine, ten, eleven, twelve, 13, 14, 15, or more filters. In one embodiment,device 100 can include a separate/different filter for each input associated withdevice 100. -
Hub 106 can be located before or after one or more filters described herein. In other embodiments,hub 106 can be placed before some filters and a second hub can be placed after the filters. Any number of hubs and filters can be used in any number of combinations. -
Hub 106, which can also be referred to as a manifold, can include two or more inlet lines and two or more outlet lines that enter a filter(s). In one embodiment, ahub 106 can be illustrated as inFIG. 2A andFIG. 2B .Hub 106 includes afront side 202 and aback side 204. Here,hub 106 includes a wedge shape that has a larger surface area onfront side 202 when compared toback side 204. However,hub 106 can have other shapes such as a sphere, a cube, a cone, an ellipse, a spade, or the like. - In some embodiments, the internal channels of the hub can be built into a filter. For example, in some embodiments, different inlet lines can merge at a filter. In such an embodiment, the filter can help merge the inlet lines. In still other embodiments, the filters can be built into the hub. The lines running through the hub can include filters such that when the medications exit the hub, they have been filtered.
-
Front side 202 can include at least two or more inlet lines. In one embodiment,front side 202 includes afirst inlet 206 which is fed byfirst inlet line 108, asecond inlet 208 which is fed bysecond inlet line 110, athird inlet 210 which is fed bythird inlet line 112, afourth inlet 212 which is fed byfourth inlet line 114, afifth inlet 214 which is fed byfifth inlet line 116, asixth inlet 216 which is fed bysixth inlet line 118, aseventh inlet 218 which is fed byseventh inlet line 120, and aneighth inlet 220 which is fed byeighth inlet line 122. - In this embodiment, back
side 204 includes afirst outlet 222 and asecond outlet 224. However, other embodiments can include more outlets such as three, four, five, six, seven, eight, nine, ten, eleven, twelve, 13, 14, 15, or more outlets. In still other embodiments,hub 106 may only include one outlet. - With two outlets on
back side 204, different combinations of the eight inlets in this embodiment can be formulated during production. In one embodiment, as illustrated inFIGS. 3A-3D ,hub 106 can includefirst inlet 206,second inlet 208,third inlet 210,fourth inlet 212,fifth inlet 214,sixth inlet 216,seventh inlet 218, andeighth inlet 220. Here,fourth inlet 212 andeighth inlet 220 are combined withinhub 106 and fed to a first filter throughfirst outlet 222. Likewise,first inlet 206,second inlet 208,third inlet 210,fifth inlet 214,sixth inlet 216, andseventh inlet 218 are combined withinhub 106 and fed to a second filter throughsecond outlet 224. Any combination of inlet and outlet numbers can be used to deliver medications throughhub 106. - In one embodiment,
fourth inlet 212 andeighth inlet 220 are fed tofirst filter 124 and the remaining inlets can be fed intosecond filter 128. In another embodiment,fourth inlet 212 andeighth inlet 220 are fed to a first filter and the remaining inlets can be fed into a second filter. -
Hub 106 can have different shapes depending on aesthetic and/or user needs. For example,front side 202 can be curved, arched, pinched, spade-like, or triangular. Example configurations are illustrated inFIGS. 3A-E . In one embodiment, as illustrated inFIG. 3B ,front side 202 can be triangular with anapex point 302. Having an apex point can allow for better placement of inlet ports when many inlets ports are in close proximity. In another embodiment, as illustrated inFIG. 3D ,front side 202 can simply be a flat surface. - Filters used herein can also have any number of shapes. In one embodiment, the shape of a filter can aid in the flow of a particular fluid through the filter. As illustrated in
FIG. 1 , filters can have a substantially triangular shape. The filter can include channels and/or flow paths that run in the direction of flow. There,first side 132 can have a larger area thansecond side 134 to direct flow fromhub 106 tooutlet 102 in an efficient manner and/or to allow for a larger area onfirst side 132 to allow more filtering to occur when medications first reach the filter. - In other embodiments, filters can have other shapes such as square or substantially square, rectangular or substantially rectangular, circle or substantially circular, elliptical or substantially elliptical, trapezoidal or substantially trapezoidal, spade or substantially spade, or the like.
- Filters can also have different sized pores. Larger pore sizes can be used to filter substances such as lipid globules and other larger materials. Smaller pore sizes can be used to filter bacteria and/or microbes. A filter can have a 0.1 μm, 0.2 μm, 0.3 μm, 0.4 μm, 0.5 μm, 0.6 μm, 0.7 μm, 0.8 μm, 0.9 μm, 1.0 μm, 1.1 μm, 1.2 μm, 1.3 μm, 1.4 μm, 1.5 μm, 2 μm, 2.5 μm, 3 μm, 3.5 μm, 4 μm, 4.5 μm, 5 μm, 5.5 μm, 6 μm, or larger pore size. In one embodiment,
first filter 124 is a 0.2 μm filter andsecond filter 128 is a 5 μm filter. - In other embodiments, the filters can provide much larger pore sizes for different liquid substances such as, but not limited to blood or colloid products. For example, pore sizes can be 50 μm, 100 μm, 150 μm, 200 μm, 250 μm, 300 μm, 350 μm, 400 μm, 450 μm, 500 μm, or larger, or between 50 μm and 300 μm, or between 100 μm and 500 μm.
- In some embodiments, filters described herein can filter both particles and air. Filtering particles can prevent infusion of particulate matter than can disrupt blood flow into the vasculature of a patient. Filtering air in addition to particles can prevent infusion of air bubbles into the vasculature of a patient. Filtering air and/or particles can be particular importance for neonates and patient's with congenital heart disease.
- The filters described herein can be set up in series or can be set up in different channels that converge at or
near outlet 102. Further, at least two ormore inlet lines 104 that converge athub 106 can be fed to different filters depending on location of the inlet line, the inner diameter of the inlet line, or the like. - Any number of filters used in the described devices can feed into
outlet 102. The exit of filters described herein can feed intooutlet 102 through a y-connector orjunction 136.Junction 136 can allow multiple filter exit lines to converge intooutlet 102 with minimal dead space volume. -
Outlet 102 can be any connection type that can interface with a patient's IV tubing. In one embodiment,outlet 102 can be a male luer lock. In another embodiment,outlet 102 can rotate freely around the axis of the IV tubing without loosening the connection. In other words,device 100 can freely rotate around the axis of the IV tubing without loosening the luer lock connection. In some embodiments, this luer lock can be called a spinning luer lock. - A spinning luer lock or spinning luer connector can prevent the unintentional disconnection of the device from IV tubing as a result of internal pressure unwinding. An example spinning luer lock connector 400 is illustrated in
FIGS. 4A-4F . Luer connector 400 includes acollar 402 that has a cup like shape that surroundsdelivery protrusion 404.Collar 402 can includeinternal threads 406 that can accept a female luer fitting that would exist on an IV inlet port. - In some embodiments,
collar 402 can include within it a portion of a ratcheting mechanism including agear 408 that runs around the internal circumference ofcollar 402.Gear 408 can lock within it apawl 410 associated withdelivery protrusion 404. An example pawl is illustrated inFIG. 4D wheredelivery protrusion 404 is illustrated without a collar. Heredelivery protrusion 404 includes anopen delivery outlet 412 atproximal end 414 and an O-ring orrib portion 416 that prevents a collar from progressing downdelivery protrusion 404 fromdistal end 418 and seals the connection.Distal end 418 can be a continuous tube or be connected todevice 100 directly. - As a
device 100 is attached to afemale luer connection 424 on anIV line 426,screw portion 422 is twisted intointernal threads 406 untilluer connection 424 is tight and secure. Even when the luer connection is tight and secure,pawl 410 engagesgear 408 thereby preventing disengagement of the luer lock without physically holdingcollar 402 to allow disengagement of the luer lock. However, without intentionally disengaging the luer lock,device 100 can spin freely around the axis of the IV line without coming loose. - In some embodiments, the hub can be situated within the body of the device itself or can be operably attached to the device's body. As illustrated in
FIG. 5 ,hub 502 is attached todevice body 504 by one ormore lines 506. Such a manifold or hub can be referred to as external. In some embodiments, a device may have two, three, four, five, six, or more external hubs connected by a line.Line 506 can be permanently attached to bothhub 502 anddevice body 504 or can be detachable from one or both ofhub 502 ordevice body 504. - In some embodiments, multiple external hubs can assist a user in spacing of syringes. In other words, if eight different medications are to be delivered and eight closely situated syringes are difficult to navigate, they can be split between external manifolds to free up maneuvering space.
- The devices herein including body portions, encasements, hubs/manifolds, and the like can be formed of rigid polymers. Exemplary polymers include, but are not limited to polyurethanes, silicones, polyesters such as polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers, ethylene-co-vinylacetate, polybutylmethacrylate, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins, polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate, cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; carboxymethyl cellulose; synthetic and natural rubbers such as polysiloxanes, latex, polymerized isoprene, bromo isobutylene isoprene, chloro isobutylene isoprene, polychloroprene, chlorosulphonated polyethylene, ethylene propylene, ethylene propylene diene monomer, fluoro silicone, hydrogenated nitrile butadiene, polyisoprene, isobutylene isoprene butyl, methyl vinyl silicone, acrylonitrile butadiene, acrylonitrile butadiene carboxy monomer, styrene butadiene, epichlorodydrin; and combinations thereof. The polymer or combination of polymers chosen to form portions of the devices must be rigid enough to hold a particular configuration and perform its intended function. In some embodiments, the polymer used is a thermal set rigid plastic.
- Further, as illustrated in
FIG. 5 ,hub 502 can include one ormore inlets 508 along a horizontal line. Inlets can be situated in a horizontal line in order to provide space to attach the multiple syringes needed for a particular patient. - In some embodiments, inlets described herein can be a location where a tubing line enters a hub or manifold or can be attachment points for the syringes themselves. If the inlets on a hub or manifold are syringe attachment points, they can be spaced apart sufficient to allow adjacent syringes to be attached to the hub or manifold without obstruction. For example,
hub 502 in some embodiments could have acurved hub surface 510 to allow more spacing between adjacent inlets. - In some embodiments, each inlet line includes a connector for syringes, for example a needleless syringe connector. Needleless syringes can be used to prevent unintentional needle sticks and convenience for connecting and disconnecting the syringe from the presently described devices. Common luer connectors are not conducive to disinfecting prior to use. Although many luer connectors are sterile from the manufacturer, once opened in a medically relevant area, contamination can occur during device preparation and/or use. The needleless connectors used herein can have a surface that is conducive to scrubbing with disinfectant prior to use.
- Any needless syringe connector can be used, for example, compression fittings, luer lock connectors, BD Q-SYTE® Luer Access Split Septum (Becton, Dickinson and Company, Franklin Lakes, N.J.), INTERLINK® Needleless IV Access Devices (Becton, Dickinson and Company, Franklin Lakes, N.J.), CARESITE® Luer Access Device (B. Braun Medical, Inc., Bethlehem, Pa.), INVISION-PLUS® IV Connector with or without Neutral Advantage Technology Rymed Technologies, LLC, Franklin Tenn.), SAFELINE® Split Septum Needleless Connector (B. Braun Medical, Inc., Bethlehem, Pa.), ULTRASITE® Ag Antibacterial Luer Access Device (LAD) (B. Braun Medical, Inc., Bethlehem, Pa.), piggyback connectors, MAXPLUS® needless connector (Medegen, Ontario, CA), or the like. In some embodiments, combinations of the technologies used in the above connections can be used.
- Further, the inlet lines described herein can each include an anti-reflux valve to prevent back flow of medicament into the syringe once it has been delivered to the inlet line. Any anti-reflux valve can be used. In some embodiments, anti-reflux valves can be included within the needleless syringe connector. In other embodiments, the anti-reflux valves can be independent to the connectors.
- In some embodiments, the outlet lines described herein can include an anti-reflux valve to prevent back flow of medicament into the device once it has been delivered to the patient's IV line. Any anti-reflux valve can be used. In some embodiments, anti-reflux valves can be included within the connector used to attach the device to the patient's IV line. In other embodiments, the anti-reflux valves can be independent to the connector.
- Inlet port tubing described herein can be tubing with a minimal internal volume such as having the smallest internal diameter. In some embodiments, tubing can be microtubing. Although the tubing can have the smallest internal diameter needed, different internal diameter tubing can be used as appropriate for a particular medication being delivered through an inlet. For example, a more viscous material may require tubing with a larger internal diameter than an aqueous based medication.
- Much like the tubing described herein, channels though hubs, y-connectors, and the like can have the smallest internal diameter required for delivery of medications.
- Tubing and channels described can have internal diameters of less than about 0.05 mm, less than about 0.1 mm, less than about 0.2 mm, less than about 0.3 mm, less than about 0.4 mm, less than about 0.5 mm, less than about 0.6 mm, less than about 0.7 mm, less than about 0.8 mm, less than about 0.9 mm, less than about 1 mm, between about 0.05 mm and about 0.5 mm, or between about 0.05 mm and about 0.1 mm.
- If tubing is used for inlets, the length of the tubing can be minimized to reduce dead volume. Inlet tubing lengths can be less than about 15 cm, less than about 14 cm, less than about 13 cm, less than about 12 cm, less than about 11 cm, less than about 10 cm, less than about 9 cm, less than about 8 cm, less than about 7 cm, less than about 6 cm, less than about 5 cm, less than about 4 cm, less than about 3 cm, or less than about 2 cm.
- Although microtubing can be used, in some embodiments, macrotubing can also be used. Larger tubing may be desired if multiple medications are being pushed through the filters or if macrotubing is required for a more viscous medication. Thus, if microtubing is used for some inlets and macrotubing is used for other inlets, the device may include macrotubing at a device outlet in order to accommodate the more viscous medications.
- In one embodiment, inlet ports/connectors can be configured for single use. For example, an inlet connector can include single direction locking configurations or connections that lock and break into that configuration preventing further use of the connection after its initial use. This single use inlet connection prevents subsequent use of a device as described herein. Further, this single use inlet connection prevents cross-contamination of medications in delivery syringes that may subsequently be connected to an inlet that was not single use.
- In one embodiment, inlets, inlet lines, and/or inlet ports can be color coded. Color coding can assist a user in identifying a particular feature of the device and reduce error in device usage.
- In some embodiments, color coding can be used to identify a particular inlet's affiliation with a filter(s). As devices herein can have multiple different filters with different inlets feeding different filter types/sizes, different inlets, inlet lines, and/or inlet ports can be color coded to represent to a user which inlets feed which filter.
- In other embodiments, color coding can be used to match particular medications with particular inlets. For example, color coding can be used to identify a particular order of medication delivery. In some embodiments, syringes can be color coded to match particular inlet colors. Such color matching can ensure that medications are delivered throughout a predetermined inlet using the visual color cue.
- In still further embodiments, inlets can include particular syringe locking mechanisms that match syringe locking mechanisms in order to prevent miss-attachment of a medication to an inappropriate inlet. For example, inlets feeding a larger pore size filter can include one type luer connection and inlets feeding a smaller pore size filter can include a different luer connection, wherein the two luer connections are not interchangeable. Such locking mechanism usage can ensure that medications are delivered throughout a predetermined filter by preventing attachment of a medication to an inappropriate filter.
- In one embodiment,
device 100 as illustrated inFIG. 6 is assembled with syringes attached.Device 100 includes a body portion that includes filters as described herein.Hub 106 includesfirst inlet line 108 with afirst syringe 606 attached tofirst connector 608,second inlet line 110 with asecond syringe 614 attached tosecond connector 616,third inlet line 112 with athird syringe 618 attached tothird connector 620,fourth inlet line 114 with afourth syringe 626 attached tofourth connector 628,fifth inlet line 116 with afifth syringe 602 attached tofifth connector 604,sixth inlet line 118 with asixth syringe 610 attached tofifth connector 612,seventh inlet line 120 with aseventh syringe 622 attached toseventh connector 624, andeighth inlet line 122 with aneighth syringe 630 attached toeighth connector 632. Because syringes can be attached simultaneously, there is no need to swab an inlet port with time sensitive medications already delivered to a patient. In some embodiments, there is not sufficient time to swab a connector between switching each of eight medications. - Further with multiple syringes attached to device, as in
device 100 illustrated inFIG. 6 , movement of the device can cause the connector atoutlet 102 to come loose unless a spinning connector such as spinning luer lock connector 400 described herein is used. Further, a user may desire to turn the assembled device over which would otherwise cause the connector atoutlet 102 to come loose. However, with the spinning connectors described herein, the assembled device can be turned over as desired without disconnection. - The devices described herein can be sterilized using any common sterilization technique without substantially degrading the device. In one embodiment, the sterilization method can be autoclaving, gamma radiation, or ethylene oxide. The devices can be sterilized before or after packaging.
- In one embodiment, devices as described herein can be provided as kits for use. Any kit can include an appropriate packaging and instructions for use. Other information can be provided with the kits such as device dimensions, filter specifics, regulatory clearances/approvals, company information, marketing materials, and the like.
- In some embodiments, a kit can include a device such as
device 100 in an appropriate packaging with at least instructions for use. - In other embodiments, a kit can include a device such as
device 100 in an appropriate packaging with a number of syringes that matches the number of inlets allowing only one syringe use per inlet. The kit can also include at least instructions for use. - In another embodiment, a kit can include a device such as
device 100 in an appropriate packaging with colored inlet lines that represent what lines go to what filters. The kit can also include at least instructions for use. - In another embodiment, a kit can include a device such as
device 100 in an appropriate packaging with colored inlet lines. A number of syringes color coded with the inlet lines can also be included. The kit can also include at least instructions for use. - In another embodiment, a kit can include a device such as
device 100 including pre-filled syringes with medications directly from the pharmacy already attached to the device using a locked connector that cannot be removed from the device. The kit can also include at least instructions for use. - In another embodiment, a kit can include a device such as
device 100 with colored inlet lines. A number of syringes color coded with the inlet lines can also be included that have been pre-filled by the pharmacy. The kit can also include at least instructions for use. - Methods of using the devices described herein to deliver multiple medications are also described. In one embodiment, a device as described herein, for
example device 100 or device 600 can be unpackaged and its outlet port hooked into a patient's IV line using a luer style connector. Other connectors can also be used. Then, a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. Then, a provider delivers combinations of medications as needed by a patient. - This method allows all the medications or at least a majority of the medication syringes to be attached to the device and hence the IV line without the need to scrub a port to attach a separate syringe when a time sensitive medication has already been administered to a patient.
- In another embodiment, a device as described herein, for
example device 100 or device 600 can be unpackaged. Then, a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. The device's outlet port is then hooked into a patient's IV line. Then, a physician, advanced practice nurse, nurse, and/or provider can deliver combinations of medications as needed by a patient. - In other embodiments, a device as described herein, for
example device 100 or device 600 can be unpackaged and its outlet port hooked into a patient's IV line. Then, a first inlet port with a particular color is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe having a matching color is attached to the scrubbed port. This process is repeated until all ports have been sterilized and syringes attached. Then, a physician, advanced practice nurse, nurse, and/or provider delivers combinations of medications as needed by a patient. - In still another embodiment, a device as described herein, for
example device 100 or device 600 can be unpackaged. Then, a first specifically colored inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe of the matching color is attached to the scrubbed port. This process is repeated using matching syringes and ports until all ports have been sterilized and syringes attached. The device's outlet port is then hooked into a patient's IV line. Then, a physician, advanced practice nurse, nurse, and/or provider can deliver combinations of medications as needed by a patient. - The devices described herein can also interface with automated instruments. The devices can interface between an automated instrument and a patient's IV line. For example, device inlets can be connected to automated instrument outlets after appropriate port swabbing and the outlet of the device can be connected to the patient's IV line again after appropriate swabbing. The instrument can then deliver varying amounts of medications through the device and into the patient's IV line.
- The devices described herein can also be included within an automated instrument and output contents to a patient's IV line. For example, device inlets can be connected within an automated instrument and the outlet of the device can be connected to the patient's IV line again after appropriate swabbing when the automated instrument is brought to a patient. The instrument can then deliver varying amounts of medications through the device and into the patient's IV line.
- In some embodiments, two or more devices can be coupled together to add additional ports to a system. For example, a device with two inlets can have an inlet coupled to an outlet port of another device with two inlets. Subsequently, any number of additional devices can be added and chained together as appropriate. In one embodiment, there could be multiple automated instrument that deliver from large volume reservoir bags to small volume syringes via micro and/or macro tubing that all attach to one or a combination of devices that allow for one connection to the patient.
- Prior to surgery in the operating room, a desired IV inlet port is aseptically prepared and/or scrubbed for at least 15 seconds to thoroughly disinfect the port. Then, a device as described herein is removed from its sterile packaging and attached to the IV inlet port. A patient who is prepped for joint replacement then enters the operating room.
- Then, a first inlet port is aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an anesthesia such as propofol is attached to the first scrubbed port.
- A second inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an antibiotic such as cefazolin is attached to the second scrubbed port.
- A third inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a local anesthesia such as lidocaine is attached to the third scrubbed port.
- A fourth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a neuromuscular blocking agent such as rocuronium is attached to the fourth scrubbed port.
- A fifth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including an anxiolytic/amnesic such as midazolam is attached to the fifth scrubbed port.
- A sixth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a narcotic such as fentanyl is attached to the sixth scrubbed port.
- A seventh inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including back up supply of anesthetic such as propofol attached to the seventh scrubbed port.
- An eighth inlet port is then aseptically prepared and/or scrubbed with an appropriate disinfectant for at least 15 seconds and a sterile medication syringe including a blood pressure support medication such as ephedrine is attached to the eighth scrubbed port.
- The eighth port can instead be loaded with an anti-nausea medication such as zofran. Alternatively, a device with nine inlet ports can be provided.
- Further, the provider can turn the device including all syringes over without risking loosening of the outlet port to the IV inlet because of the rotating connector on the device.
- Then, a provider delivers combinations of medications as needed by a patient without the need to remove and replace medications and waste time aseptically preparing and/or scrubbing ports once anesthesia has been initialized and anesthetizes the patient for surgery with a minimized risk of infection or patient risk.
- A patient is rushed for a crash caesarean section under general anesthesia. The provider places an order to the pharmacy for a cocktail of medications to anesthetize the patient for surgery. A device as described herein with four syringes already connected is delivered to the operating room prior to the patient's arrival to the operating room. The preassembled device is delivered as follows: a first inlet port includes a sterile medication syringe including an anesthesia such as propofol; a second inlet port includes a sterile medication syringe including an antibiotic such as cefazolin; a third inlet port includes a sterile medication syringe including a narcotic such as fentanyl; a fourth inlet port includes a sterile medication syringe including a neuromuscular blocking agent such as succinylcholine.
- The desired IV inlet port is aseptically prepared and/or scrubbed for at least 15 seconds to thoroughly disinfect the port. Then, the device is attached to the disinfected IV inlet port. The provider can turn the device including all syringes over without risking loosening of the outlet port to the IV inlet because of the rotating connector on the device.
- Then, a provider delivers combinations of medications as needed by a patient without the need to remove and replace medications and waste time aseptically preparing and/or scrubbing ports once anesthesia has been initialized and anesthetizes the patient for surgery with a minimized risk of infection or patient risk.
- Procedure related sedation which can occur in multiple hospital settings both in the emergency department, intensive care, and/or locations where anesthesia is administered for patients who require deep sedation only for the length of a procedure. Medications such as propofol can be combined with ketamine, etomidate, dexmeditomidine, fentanyl, midazalam, lidocaine or saline. Providing brief, titratable, deep sedation can be delivered by programmable automated instruments or directly by the provider.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
- The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
- Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
- Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
- In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
Claims (10)
1. A method of delivering at least two different time sensitive medications, the method comprising:
delivering at least a first medication in a first syringe and a second medication in a second syringe through a device into an intravenous line without disconnecting the first syringe or the second syringe.
2. The method of claim 1 , wherein the first medication is an anesthetic.
3. The method of claim 2 , wherein the anesthetic is propofol.
4. The method of claim 1 , wherein the device includes a body section including at least two inlet ports;
wherein at least one of the at least two inlet ports includes an anti-reflux valve and is operably connected to a first filter; and
wherein at least another inlet port of the at least two inlet ports includes an anti-reflux valve and is operably connected to a second filter.
5. The method of claim 4 , wherein the device includes a rotating outlet port joined to the first filter and the second filter by a y-connector and configured to connect to the intravenous line.
6. The method of claim 1 , further comprising delivering at least a third medication in a third syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, or the third syringe.
7. The method of claim 6 , further comprising delivering at least a fourth medication in a fourth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, or the fourth syringe.
8. The method of claim 7 , further comprising delivering at least a fifth medication in a fifth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, or the fifth syringe.
9. The method of claim 1 , further comprising delivering at least a third medication in a third syringe, a fourth medication in a fourth syringe, a fifth medication in a fifth syringe, a sixth medication in a sixth syringe, a seventh medication in a seventh syringe, and an eighth medication in an eighth syringe through the device into the intravenous line without disconnecting the first syringe, the second syringe, the third syringe, the fourth syringe, the fifth syringe, the sixth syringe, the seventh syringe, or the eighth syringe.
10. The method of claim 1 , wherein the delivering reduces a patient's chance of infection, reduces the chance of particle infusion, reduces the chance of air infusion, or a combination thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/697,755 US20220331514A1 (en) | 2015-06-15 | 2022-03-17 | Multiport delivery device |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175941P | 2015-06-15 | 2015-06-15 | |
US15/156,086 US10369272B2 (en) | 2015-06-15 | 2016-05-16 | Multiport delivery device |
US16/453,850 US11278662B2 (en) | 2015-06-15 | 2019-06-26 | Multiport delivery device |
US17/697,755 US20220331514A1 (en) | 2015-06-15 | 2022-03-17 | Multiport delivery device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/453,850 Continuation US11278662B2 (en) | 2015-06-15 | 2019-06-26 | Multiport delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220331514A1 true US20220331514A1 (en) | 2022-10-20 |
Family
ID=57516284
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/156,086 Active 2037-06-01 US10369272B2 (en) | 2015-06-15 | 2016-05-16 | Multiport delivery device |
US16/453,850 Active 2037-03-18 US11278662B2 (en) | 2015-06-15 | 2019-06-26 | Multiport delivery device |
US17/697,755 Pending US20220331514A1 (en) | 2015-06-15 | 2022-03-17 | Multiport delivery device |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/156,086 Active 2037-06-01 US10369272B2 (en) | 2015-06-15 | 2016-05-16 | Multiport delivery device |
US16/453,850 Active 2037-03-18 US11278662B2 (en) | 2015-06-15 | 2019-06-26 | Multiport delivery device |
Country Status (3)
Country | Link |
---|---|
US (3) | US10369272B2 (en) |
EP (1) | EP3307349A4 (en) |
WO (1) | WO2016204906A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10773863B2 (en) | 2011-06-22 | 2020-09-15 | Sartorius Stedim North America Inc. | Vessel closures and methods for using and manufacturing same |
US11577953B2 (en) | 2017-11-14 | 2023-02-14 | Sartorius Stedim North America, Inc. | System for simultaneous distribution of fluid to multiple vessels and method of using the same |
US11319201B2 (en) | 2019-07-23 | 2022-05-03 | Sartorius Stedim North America Inc. | System for simultaneous filling of multiple containers |
WO2019099406A1 (en) * | 2017-11-14 | 2019-05-23 | Sartorius Stedim North America Inc. | Fluid transfer assembly with a junction having multiple fluid pathways |
US11691866B2 (en) | 2017-11-14 | 2023-07-04 | Sartorius Stedim North America Inc. | System for simultaneous distribution of fluid to multiple vessels and method of using the same |
US20190298911A1 (en) * | 2018-03-02 | 2019-10-03 | Somnus Medical, LLC | IV Set or IV Set System with Unidirectional Access Port |
CN109621075B (en) * | 2019-01-28 | 2020-12-29 | 胡顺鹏 | Infusion device for continuous administration in medical nursing |
CN116568957A (en) * | 2020-09-23 | 2023-08-08 | 波士顿科学医疗设备有限公司 | Multi-way connector |
US11147959B1 (en) | 2021-03-31 | 2021-10-19 | Jason Lakis | Syringe apparatus for disinfection of central line port needleless connector and method of disinfecting a central line port needleless connector |
CN115226518B (en) * | 2022-08-25 | 2023-07-04 | 广东益林科技有限公司 | Electric tree body liquid injector |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795441A (en) * | 1987-04-16 | 1989-01-03 | Bhatt Kunjlata M | Medication administration system |
US20020156431A1 (en) * | 1998-09-17 | 2002-10-24 | Feith Raymond P. | Multi-valve injection/aspiration manifold with needleless access connection |
US20020173729A1 (en) * | 2001-05-18 | 2002-11-21 | Hanna Viertio-Oja | Closed loop drug administration method and apparatus using eeg complexity for control purposes |
US6508791B1 (en) * | 2000-01-28 | 2003-01-21 | Ramon Guerrero | Infusion device cartridge |
DE202004014868U1 (en) * | 2003-09-22 | 2004-11-25 | Krönke, Delia | System for administering medicaments, in particular, catecholamines to a patient incorporates a microvolume switch with at least one adapter with one outlet and at least two inlet lines |
US20050267445A1 (en) * | 2002-11-19 | 2005-12-01 | Biometrix Ltd. | Manifold hub for patient fluid administration |
US20060089604A1 (en) * | 2004-10-26 | 2006-04-27 | Intrasafe Medical, Llc | Infusion device for administering fluids to a patient |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957082A (en) * | 1974-09-26 | 1976-05-18 | Arbrook, Inc. | Six-way stopcock |
CN2203882Y (en) | 1994-11-22 | 1995-07-26 | 蒋文俊 | Disposable air filtration device for transfusion |
US5620427A (en) | 1995-04-27 | 1997-04-15 | David R. Kipp | Luer lock system |
US6402207B1 (en) * | 1997-06-09 | 2002-06-11 | Qd Enterprises, Llc | Safety indexed medical connectors |
EP1161275A1 (en) * | 1999-03-17 | 2001-12-12 | Becton Dickinson and Company | Catheter with improved junction housing |
IL133495A (en) * | 1999-12-13 | 2006-12-31 | Menahem Kraus | Membrane support for drip chamber |
US7316679B2 (en) * | 2001-01-22 | 2008-01-08 | Venetec International, Inc. | Medical device connector fitting |
WO2003011377A1 (en) * | 2001-07-31 | 2003-02-13 | Scott Laboratories, Inc. | Apparatuses and methods for providing iv infusion administration |
US6656158B2 (en) | 2002-04-23 | 2003-12-02 | Insulet Corporation | Dispenser for patient infusion device |
GB0604929D0 (en) * | 2006-03-13 | 2006-04-19 | Renishaw Plc | Method and apparatus for fluid delivery |
CA2665697A1 (en) | 2006-10-10 | 2008-04-17 | Infusive Technologies, Llc | Multi-chamber, sequential dose dispensing syringe |
US20090137969A1 (en) * | 2007-11-26 | 2009-05-28 | Colantonio Anthony J | Apparatus and method for sterilizing a tubular medical line port |
US9044542B2 (en) * | 2007-12-21 | 2015-06-02 | Carticept Medical, Inc. | Imaging-guided anesthesia injection systems and methods |
US8465461B2 (en) * | 2010-07-27 | 2013-06-18 | Becton, Dickinson And Company | Blunt needle safety drug delivery system |
US8337701B2 (en) * | 2011-03-14 | 2012-12-25 | Pall Corporation | Intravenous filter |
WO2013043367A1 (en) * | 2011-09-20 | 2013-03-28 | Micro-Coax, Inc. | Locking connector |
SE1150932A1 (en) * | 2011-10-10 | 2013-01-29 | Micael Toernblom | Valve for administering a variety of drug fluids |
US9477049B2 (en) * | 2013-12-20 | 2016-10-25 | Senko Advanced Components, Inc. | Lockable connectors and connection assemblies |
-
2016
- 2016-05-16 WO PCT/US2016/032762 patent/WO2016204906A1/en active Application Filing
- 2016-05-16 EP EP16812110.1A patent/EP3307349A4/en active Pending
- 2016-05-16 US US15/156,086 patent/US10369272B2/en active Active
-
2019
- 2019-06-26 US US16/453,850 patent/US11278662B2/en active Active
-
2022
- 2022-03-17 US US17/697,755 patent/US20220331514A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4795441A (en) * | 1987-04-16 | 1989-01-03 | Bhatt Kunjlata M | Medication administration system |
US20020156431A1 (en) * | 1998-09-17 | 2002-10-24 | Feith Raymond P. | Multi-valve injection/aspiration manifold with needleless access connection |
US6508791B1 (en) * | 2000-01-28 | 2003-01-21 | Ramon Guerrero | Infusion device cartridge |
US20020173729A1 (en) * | 2001-05-18 | 2002-11-21 | Hanna Viertio-Oja | Closed loop drug administration method and apparatus using eeg complexity for control purposes |
US20050267445A1 (en) * | 2002-11-19 | 2005-12-01 | Biometrix Ltd. | Manifold hub for patient fluid administration |
DE202004014868U1 (en) * | 2003-09-22 | 2004-11-25 | Krönke, Delia | System for administering medicaments, in particular, catecholamines to a patient incorporates a microvolume switch with at least one adapter with one outlet and at least two inlet lines |
US20060089604A1 (en) * | 2004-10-26 | 2006-04-27 | Intrasafe Medical, Llc | Infusion device for administering fluids to a patient |
Non-Patent Citations (1)
Title |
---|
Machine translation of DE 202004014868 U1. Retrieved on November 21, 2023 from espacenet. (Year: 2023) * |
Also Published As
Publication number | Publication date |
---|---|
US11278662B2 (en) | 2022-03-22 |
EP3307349A1 (en) | 2018-04-18 |
WO2016204906A1 (en) | 2016-12-22 |
EP3307349A4 (en) | 2019-03-27 |
US10369272B2 (en) | 2019-08-06 |
US20190314570A1 (en) | 2019-10-17 |
US20160361488A1 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11278662B2 (en) | Multiport delivery device | |
JP2013535277A (en) | Blunt needle safety drug delivery system | |
US20240033437A1 (en) | Integrated disinfection device | |
JP2024001336A (en) | Universal single time use cap for male and female connectors | |
CN112154008A (en) | Universal cap for male and female connectors | |
EP3773868B1 (en) | Universal single-use cap for male and female connectors | |
JP2023521876A (en) | caps for male and female threaded fittings | |
JP2023508041A (en) | Disinfection of syringe tip | |
CN112154009B (en) | Universal disposable lid for male and female connectors | |
US11583669B2 (en) | Prepackaged needleless intravenous tubing with in-line disinfectant port caps | |
US20240131317A1 (en) | Flush syringe with multiple scrubbing devices | |
CN112135657B (en) | Universal disposable cover for male and female connectors | |
WO2024086254A1 (en) | Flush syringe with multiple scrubbing devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HAI SOLUTIONS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENSPERO INC.;REEL/FRAME:059299/0660 Effective date: 20180709 Owner name: ENSPERO INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PERRENOUD, NICHOLAS;SWANEY, PAUL;SIGNING DATES FROM 20150615 TO 20150619;REEL/FRAME:059299/0647 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |